REI Specialist Q&A — IVF Stimulation, PGT-A, POSEIDON, RIF, RPL | FertilityConnect

Q: What is the latest evidence-based protocol for poor ovarian responders according to the Bologna criteria?

The Bologna criteria (Ferraretti et al., Human Reproduction 2011) define poor ovarian response as ≥2 of: advanced maternal age (≥40) or other risk factor; poor ovarian response in a prior cycle (≤3 oocytes with conventional stimulation); or abnormal ovarian reserve test (AFC <5–7 follicles or AMH <0.5–1.1 ng/mL). While clinically useful, Bologna criteria have been substantially refined by the POSEIDON classification (2016), which offers a more granular, actionable framework. ESHRE 2024 now recommends POSEIDON for clinical stratification. Evidence-based protocol elements supported by current literature: — Maximum FSH dose (up to 450 IU/day) with GnRH antagonist protocol: reduces cycle cancellation without improving live birth rate over lower doses (Pandian et al., Cochrane 2010, updated evidence 2022). — rLH supplementation: meta-analysis (Mochtar et al., Cochrane 2021) shows benefit in hypogonadotrophic patients and women >35. — Luteal-phase priming with oestradiol or progesterone before antagonist cycle: modest evidence of improved synchronisation. — Growth hormone adjuvant: remains investigational. ESHRE 2024 does not recommend routine use — evidence is inconsistent and limited to small trials. — Natural or minimal stimulation IVF: an alternative for selected Group 3/4 patients unwilling to undergo repeated conventional stimulation.

Q: What is the role of recombinant LH supplementation in IVF cycles?

LH plays a permissive role in late folliculogenesis — the "LH ceiling and threshold" concept underpins rationale for rLH use. ESHRE 2024 and ASRM 2023 support selective rLH supplementation in defined groups. Evidence-based indications: — Women >35 years: declining endogenous LH with age impairs androgen substrate for oestradiol synthesis. Meta-analysis (Mochtar et al., Cochrane 2021) shows rLH significantly improves clinical pregnancy rate in this group. — Hypogonadotrophic hypogonadism (WHO Group I): rFSH + rLH is mandatory for follicular development. — Predicted or confirmed poor responders (POSEIDON Groups 1–4): rLH (75–150 IU/day) added from stimulation day 1 or after confirmed follicular plateau. — GnRH agonist long protocol: pituitary desensitisation suppresses endogenous LH profoundly; add-back rLH is physiologically rational. Where rLH is not routinely indicated: normal-reserve, normogonadotrophic women <35 years undergoing standard antagonist protocol — endogenous LH recovery under antagonist is generally adequate (Mochtar, Cochrane 2021). rLH is available as recombinant LH (Luveris®) or combined rFSH/rLH (Pergoveris®). Dosing is typically 75–150 IU/day co-administered with FSH.

Q: Do DHEA and CoQ10 improve live birth rates in poor responders?

Both DHEA and CoQ10 are widely used ovarian reserve supplements; however the evidence for improved live birth rates remains insufficient to warrant routine recommendation per ASRM 2023 and ESHRE 2024. DHEA (dehydroepiandrosterone): Proposed mechanism is androgen priming of granulosa cells, increasing follicular responsiveness to FSH. A 2024 Cochrane review (Nagels et al.) found no significant improvement in live birth rate with DHEA supplementation (OR 1.13, 95% CI 0.72–1.76); number of oocytes retrieved may modestly increase. Current ESHRE 2024 guidance: DHEA cannot be recommended routinely due to insufficient evidence. India's ART practice commonly uses DHEA 25–75 mg/day for 6–8 weeks pre-stimulation — clinical judgement is reasonable when no euploid embryo is available. CoQ10 (ubiquinol/ubiquinone): Acts as mitochondrial antioxidant, theoretically improving oocyte energy metabolism. Ben-Meir et al. (Aging Cell 2015) showed improved oocyte quality in an aged mouse model. Human data remain limited to small RCTs showing modest improvements in oocyte number and blastulation rate, without consistent live birth benefit. ASRM 2023 considers CoQ10 investigational. Both supplements are low-risk. Where patients are counselled appropriately on the evidence limitations, a trial of CoQ10 200–600 mg/day or DHEA 25 mg/day before a subsequent cycle is a reasonable clinical decision.

Q: What is the evidence for androgen priming before IVF?

Androgen priming — most commonly with transdermal testosterone — aims to upregulate FSH receptors on granulosa cells and improve follicular sensitivity to stimulation. Proposed mechanisms include increased IGF-1 signalling and granulosa cell proliferation. Evidence summary: Transdermal testosterone: A 2021 meta-analysis (Nagels et al., Cochrane; 8 RCTs, n=667) found transdermal testosterone priming (25 mg for 5–21 days pre-stimulation) significantly increased the number of oocytes retrieved (MD +1.6, 95% CI 0.5–2.7) in poor responders. Clinical pregnancy rate showed a trend toward benefit, but live birth rate data were insufficient for firm conclusions. DHEA: As a testosterone precursor, DHEA achieves androgen priming via conversion to testosterone. Evidence is similar in magnitude to direct testosterone — see Q6. ESHRE 2024: Transdermal testosterone priming can be considered in POSEIDON Groups 3 and 4 where no euploid embryo has been obtained. It is not recommended as routine for all poor responders. ASRM 2023: Notes promising pilot data but withholds recommendation pending adequately powered RCTs with live birth as primary endpoint. Duration: 5–21 days pre-stimulation (most studies: 21 days). Dose: 5.5–10 mg/day transdermal testosterone gel.

Q: How should unexpectedly poor ovarian response be managed during stimulation?

Unexpectedly poor response — defined as ≤3 follicles ≥14 mm on day 6–8 of stimulation with initially adequate reserve — occurs in 5–10% of IVF cycles. This phenotype corresponds to POSEIDON Groups 1 and 2 (expected adequate responders). Management options per ESHRE 2024: 1. Dose increase: Step-up to maximum FSH dose (450 IU/day) if not already at ceiling. Evidence for benefit is limited once response is established. 2. Add rLH: If not already included, rLH 75–150 IU/day may salvage follicular development in older patients. 3. Extend stimulation: Continue for additional 2–4 days if follicles show growth potential (≥1 mm/day). 4. Convert to natural or modified natural IVF cycle: If only 1–2 follicles are present and retrieval is planned, proceeding without further stimulation may be the most pragmatic decision. 5. Cycle cancellation: Appropriate if no follicles ≥10 mm by day 10. Cancellation avoids cost, OHSS risk from trigger, and empty follicle disappointment. 6. Coasting: No evidence to support in this scenario — applicable only to hyper-responders. Reassessment of diagnosis: Rule out asynchronous or late-developing cohort with serial ultrasound before cancellation. A bolus AFC recount and AMH on day 3 of the stimulated cycle may identify previously missed poor reserve.

Q: Which ovarian stimulation protocol yields the highest cumulative live birth rate in women above 40?

Women ≥40 years face declining oocyte competence (euploidy rate ~20–30% per blastocyst) alongside reduced ovarian reserve. Protocol selection should prioritise oocyte number without compromising quality. Evidence-based approach (ASRM 2023, ESHRE 2024): — GnRH antagonist protocol with GnRH agonist trigger: Preferred to avoid OHSS and enable freeze-all in this age group where fresh transfer outcomes are inferior to frozen transfers. — Maximum FSH dose (300–450 IU/day): Higher starting doses are justified given DOR prevalence in this age group. — Embryo accumulation + PGT-A: The cumulative live birth rate strategy endorsed by ASRM 2023 — pool blastocysts over 2–3 cycles, then PGT-A to identify euploid embryos. A 2020 study (Capalbo et al., Hum Reprod) showed CLBR of 52% in women 40–43 after euploid transfer from accumulated cycles vs 16% without PGT-A. — DuoStim: Offers the fastest route to sufficient blastocysts for PGT-A in women with DOR. Evidence does not support superiority of long agonist protocol or flare protocols in women >40 compared to antagonist cycles. Natural IVF for women >42 with AMH <0.5 ng/mL may avoid futile stimulations, though cumulative LBR per attempt remains low (~5–8%).

Q: What is the current first-line fertility treatment for PCOS according to international guidelines?

ESHRE 2023 International Evidence-Based Guideline on PCOS and ASRM 2023 align on the following first-line hierarchy for fertility treatment in PCOS: 1. Lifestyle modification (all overweight/obese women with PCOS): Even 5% body weight reduction restores spontaneous ovulation in 55–100% of previously anovulatory women. This is the highest-evidence, lowest-risk intervention and should precede pharmacological ovulation induction. 2. Letrozole (aromatase inhibitor): First-line pharmacological ovulation induction. ESHRE 2023 upgraded Letrozole above Clomiphene as the preferred agent based on the landmark Legro et al. NEJM 2014 trial (live birth rate 27.5% vs 19.1% per cycle with Letrozole vs Clomiphene; lower multiple pregnancy rate). 3. Clomiphene citrate: Remains an acceptable alternative where Letrozole is unavailable or the patient has contraindications. 4. Metformin: Can be used alongside Letrozole or Clomiphene. ESHRE 2023 recommends metformin addition in women with BMI ≥25 or insulin resistance to improve ovulation rates and reduce OHSS risk. 5. Gonadotrophins (FSH injections) with careful monitoring: Second-line after failed oral induction. Requires careful dose titration and ultrasound monitoring to prevent multi-follicular development. 6. Laparoscopic ovarian drilling (LOD): Second-line surgical alternative to gonadotrophins. Evidence shows equivalent cumulative live birth rates with lower multiple pregnancy risk.

Question 1

What is the optimal management strategy for POSEIDON Groups 1–4 patients?

Dr. Vidhu D · Accepted Answer

The POSEIDON (Patient-Oriented Strategies Encompassing IndividualizeD Oocyte Number) classification — published in Human Reproduction Open (2016) and updated in ESHRE 2024 guidance — stratifies poor responders by age (<35 vs ≥35 years), ovarian reserve markers (AMH <1.2 ng/mL or AFC <5), and prior stimulation response.

Group 1 (young, adequate reserve, unexpected poor response): Intensify FSH dose to 300–450 IU/day. Add recombinant LH 75–150 IU/day, particularly in women >35. Evaluate for occult DOR with repeat AFC and AMH.

Group 2 (older ≥35, adequate reserve, unexpected poor response): rLH supplementation is essential given age-related LH decline. Consider GnRH antagonist protocol with flexible trigger. Reassess stimulation window.

Group 3 (young, poor reserve — AMH <1.2 ng/mL or AFC <5): Testosterone priming (transdermal 25 mg for 5–7 days pre-stimulation), DuoStim, or embryo accumulation over multiple cycles before PGT-A. Maximum FSH dose.

Group 4 (older ≥35, poor reserve): DuoStim (follicular + luteal phase retrieval in same cycle) is the most time-efficient strategy. Embryo accumulation with freeze-all and pooling before PGT-A is the ASRM-recommended approach.

Current ESHRE 2024 guidance supports individualised, biomarker-driven stimulation over fixed protocols for all POSEIDON groups. Bologna criteria have been largely superseded in clinical practice.

Question 2

What is the latest evidence-based protocol for poor ovarian responders according to the Bologna criteria?

Dr. Sarah H · Accepted Answer

The Bologna criteria (Ferraretti et al., Human Reproduction 2011) define poor ovarian response as ≥2 of: advanced maternal age (≥40) or other risk factor; poor ovarian response in a prior cycle (≤3 oocytes with conventional stimulation); or abnormal ovarian reserve test (AFC <5–7 follicles or AMH <0.5–1.1 ng/mL).

While clinically useful, Bologna criteria have been substantially refined by the POSEIDON classification (2016), which offers a more granular, actionable framework. ESHRE 2024 now recommends POSEIDON for clinical stratification.

Evidence-based protocol elements supported by current literature:
— Maximum FSH dose (up to 450 IU/day) with GnRH antagonist protocol: reduces cycle cancellation without improving live birth rate over lower doses (Pandian et al., Cochrane 2010, updated evidence 2022).
— rLH supplementation: meta-analysis (Mochtar et al., Cochrane 2021) shows benefit in hypogonadotrophic patients and women >35.
— Luteal-phase priming with oestradiol or progesterone before antagonist cycle: modest evidence of improved synchronisation.
— Growth hormone adjuvant: remains investigational. ESHRE 2024 does not recommend routine use — evidence is inconsistent and limited to small trials.
— Natural or minimal stimulation IVF: an alternative for selected Group 3/4 patients unwilling to undergo repeated conventional stimulation.

Question 3

How should ovarian stimulation be individualised based on AMH, AFC, age, and BMI?

Dr. James M · Accepted Answer

Individualised controlled ovarian stimulation (iCOS) is endorsed by ESHRE 2024 as the standard of care, replacing empirical fixed-dose protocols. AMH-guided dosing: Women with AMH <1.2 ng/mL (low reserve) — start FSH 300–450 IU/day. AMH 1.2–3.5 ng/mL (normal reserve) — FSH 150–225 IU/day. AMH >3.5 ng/mL (high reserve, PCOS risk) — FSH 100–150 IU/day with GnRH antagonist to enable agonist trigger. AFC contribution: AFC <5 corroborates DOR even if AMH is borderline low. AFC ≥16 independently predicts OHSS risk regardless of AMH. Age effect: Women ≥38 years have reduced oocyte competence independent of AMH. Even with adequate AMH, age-adjusted protocols should anticipate lower euploid blastocyst rates. BMI adjustment: ESHRE 2024 notes that BMI >30 kg/m² is associated with impaired FSH absorption after subcutaneous injection and may require dose increases of 25–50 IU. Morbid obesity (BMI >35) significantly reduces IVF outcomes and weight loss should be advised before treatment. The PIVET algorithm and Elecsys AMH Plus platform offer validated, reproducible AMH-based dosing models (Nelson et al., Fertil Steril 2015).

Question 4

What does recent evidence say about DuoStim in poor ovarian responders?

Dr. Vidhu D · Accepted Answer

DuoStim — sequential follicular-phase stimulation (FPS) followed immediately by luteal-phase stimulation (LPS) within the same menstrual cycle — was first described by Ubaldi et al. (Fertil Steril 2016) and has since accumulated a substantial evidence base for POSEIDON Groups 3 and 4.

Key evidence (2021–2024):
— Oocyte yield: LPS retrieves a comparable or greater number of mature oocytes to FPS within the same patient (mean 3–5 additional MII oocytes per full DuoStim cycle).
— Competence: Multiple studies (Vaiarelli et al., Front Endocrinol 2019; Cimadomo et al., Hum Reprod 2023) confirm euploidy rates from LPS blastocysts (40–55% in women <38) are equivalent to those from FPS.
— Timeline benefit: One DuoStim cycle is equivalent to approximately two conventional cycles — reduces time-to-transfer by 4–8 weeks.
— Safety: No adverse endocrine, endometrial, or obstetric signals identified in published series.

ESHRE 2024 position: DuoStim is clinically reasonable for POSEIDON Groups 3 and 4; large RCT evidence is still awaited. ASRM 2023 supports the approach pending higher-level data. All embryos from DuoStim must be frozen; luteal-phase hormonal milieu precludes fresh transfer.

Question 5

What is the role of recombinant LH supplementation in IVF cycles?

Dr. Sarah H · Accepted Answer

LH plays a permissive role in late folliculogenesis — the "LH ceiling and threshold" concept underpins rationale for rLH use. ESHRE 2024 and ASRM 2023 support selective rLH supplementation in defined groups.

Evidence-based indications:
— Women >35 years: declining endogenous LH with age impairs androgen substrate for oestradiol synthesis. Meta-analysis (Mochtar et al., Cochrane 2021) shows rLH significantly improves clinical pregnancy rate in this group.
— Hypogonadotrophic hypogonadism (WHO Group I): rFSH + rLH is mandatory for follicular development.
— Predicted or confirmed poor responders (POSEIDON Groups 1–4): rLH (75–150 IU/day) added from stimulation day 1 or after confirmed follicular plateau.
— GnRH agonist long protocol: pituitary desensitisation suppresses endogenous LH profoundly; add-back rLH is physiologically rational.

Where rLH is not routinely indicated: normal-reserve, normogonadotrophic women <35 years undergoing standard antagonist protocol — endogenous LH recovery under antagonist is generally adequate (Mochtar, Cochrane 2021).

rLH is available as recombinant LH (Luveris®) or combined rFSH/rLH (Pergoveris®). Dosing is typically 75–150 IU/day co-administered with FSH.

Question 6

Do DHEA and CoQ10 improve live birth rates in poor responders?

Dr. Vidhu D · Accepted Answer

Both DHEA and CoQ10 are widely used ovarian reserve supplements; however the evidence for improved live birth rates remains insufficient to warrant routine recommendation per ASRM 2023 and ESHRE 2024.

DHEA (dehydroepiandrosterone): Proposed mechanism is androgen priming of granulosa cells, increasing follicular responsiveness to FSH. A 2024 Cochrane review (Nagels et al.) found no significant improvement in live birth rate with DHEA supplementation (OR 1.13, 95% CI 0.72–1.76); number of oocytes retrieved may modestly increase. Current ESHRE 2024 guidance: DHEA cannot be recommended routinely due to insufficient evidence. India's ART practice commonly uses DHEA 25–75 mg/day for 6–8 weeks pre-stimulation — clinical judgement is reasonable when no euploid embryo is available.

CoQ10 (ubiquinol/ubiquinone): Acts as mitochondrial antioxidant, theoretically improving oocyte energy metabolism. Ben-Meir et al. (Aging Cell 2015) showed improved oocyte quality in an aged mouse model. Human data remain limited to small RCTs showing modest improvements in oocyte number and blastulation rate, without consistent live birth benefit. ASRM 2023 considers CoQ10 investigational.

Both supplements are low-risk. Where patients are counselled appropriately on the evidence limitations, a trial of CoQ10 200–600 mg/day or DHEA 25 mg/day before a subsequent cycle is a reasonable clinical decision.

Question 7

What is the evidence for androgen priming before IVF?

Dr. James M · Accepted Answer

Androgen priming — most commonly with transdermal testosterone — aims to upregulate FSH receptors on granulosa cells and improve follicular sensitivity to stimulation. Proposed mechanisms include increased IGF-1 signalling and granulosa cell proliferation.

Evidence summary:
Transdermal testosterone: A 2021 meta-analysis (Nagels et al., Cochrane; 8 RCTs, n=667) found transdermal testosterone priming (25 mg for 5–21 days pre-stimulation) significantly increased the number of oocytes retrieved (MD +1.6, 95% CI 0.5–2.7) in poor responders. Clinical pregnancy rate showed a trend toward benefit, but live birth rate data were insufficient for firm conclusions.

DHEA: As a testosterone precursor, DHEA achieves androgen priming via conversion to testosterone. Evidence is similar in magnitude to direct testosterone — see Q6.

ESHRE 2024: Transdermal testosterone priming can be considered in POSEIDON Groups 3 and 4 where no euploid embryo has been obtained. It is not recommended as routine for all poor responders.

ASRM 2023: Notes promising pilot data but withholds recommendation pending adequately powered RCTs with live birth as primary endpoint.

Duration: 5–21 days pre-stimulation (most studies: 21 days). Dose: 5.5–10 mg/day transdermal testosterone gel.

Question 8

How should unexpectedly poor ovarian response be managed during stimulation?

Dr. Sarah H · Accepted Answer

Unexpectedly poor response — defined as ≤3 follicles ≥14 mm on day 6–8 of stimulation with initially adequate reserve — occurs in 5–10% of IVF cycles. This phenotype corresponds to POSEIDON Groups 1 and 2 (expected adequate responders).

Management options per ESHRE 2024:
1. Dose increase: Step-up to maximum FSH dose (450 IU/day) if not already at ceiling. Evidence for benefit is limited once response is established.
2. Add rLH: If not already included, rLH 75–150 IU/day may salvage follicular development in older patients.
3. Extend stimulation: Continue for additional 2–4 days if follicles show growth potential (≥1 mm/day).
4. Convert to natural or modified natural IVF cycle: If only 1–2 follicles are present and retrieval is planned, proceeding without further stimulation may be the most pragmatic decision.
5. Cycle cancellation: Appropriate if no follicles ≥10 mm by day 10. Cancellation avoids cost, OHSS risk from trigger, and empty follicle disappointment.
6. Coasting: No evidence to support in this scenario — applicable only to hyper-responders.

Reassessment of diagnosis: Rule out asynchronous or late-developing cohort with serial ultrasound before cancellation. A bolus AFC recount and AMH on day 3 of the stimulated cycle may identify previously missed poor reserve.

Question 9

Which ovarian stimulation protocol yields the highest cumulative live birth rate in women above 40?

Dr. Michael C · Accepted Answer

Women ≥40 years face declining oocyte competence (euploidy rate ~20–30% per blastocyst) alongside reduced ovarian reserve. Protocol selection should prioritise oocyte number without compromising quality.

Evidence-based approach (ASRM 2023, ESHRE 2024):
— GnRH antagonist protocol with GnRH agonist trigger: Preferred to avoid OHSS and enable freeze-all in this age group where fresh transfer outcomes are inferior to frozen transfers.
— Maximum FSH dose (300–450 IU/day): Higher starting doses are justified given DOR prevalence in this age group.
— Embryo accumulation + PGT-A: The cumulative live birth rate strategy endorsed by ASRM 2023 — pool blastocysts over 2–3 cycles, then PGT-A to identify euploid embryos. A 2020 study (Capalbo et al., Hum Reprod) showed CLBR of 52% in women 40–43 after euploid transfer from accumulated cycles vs 16% without PGT-A.
— DuoStim: Offers the fastest route to sufficient blastocysts for PGT-A in women with DOR.

Evidence does not support superiority of long agonist protocol or flare protocols in women >40 compared to antagonist cycles. Natural IVF for women >42 with AMH <0.5 ng/mL may avoid futile stimulations, though cumulative LBR per attempt remains low (~5–8%).

Question 10

What is the current first-line fertility treatment for PCOS according to international guidelines?

Dr. Vidhu D · Accepted Answer

ESHRE 2023 International Evidence-Based Guideline on PCOS and ASRM 2023 align on the following first-line hierarchy for fertility treatment in PCOS:

1. Lifestyle modification (all overweight/obese women with PCOS): Even 5% body weight reduction restores spontaneous ovulation in 55–100% of previously anovulatory women. This is the highest-evidence, lowest-risk intervention and should precede pharmacological ovulation induction.

2. Letrozole (aromatase inhibitor): First-line pharmacological ovulation induction. ESHRE 2023 upgraded Letrozole above Clomiphene as the preferred agent based on the landmark Legro et al. NEJM 2014 trial (live birth rate 27.5% vs 19.1% per cycle with Letrozole vs Clomiphene; lower multiple pregnancy rate).

3. Clomiphene citrate: Remains an acceptable alternative where Letrozole is unavailable or the patient has contraindications.

4. Metformin: Can be used alongside Letrozole or Clomiphene. ESHRE 2023 recommends metformin addition in women with BMI ≥25 or insulin resistance to improve ovulation rates and reduce OHSS risk.

5. Gonadotrophins (FSH injections) with careful monitoring: Second-line after failed oral induction. Requires careful dose titration and ultrasound monitoring to prevent multi-follicular development.

6. Laparoscopic ovarian drilling (LOD): Second-line surgical alternative to gonadotrophins. Evidence shows equivalent cumulative live birth rates with lower multiple pregnancy risk.

Question 11

How does Letrozole compare with Clomiphene for live birth outcomes?

Dr. Vidhu D · Accepted Answer

The landmark NEJM 2014 RCT (Legro et al., n=750 women with PCOS) definitively established Letrozole superiority over Clomiphene:

— Cumulative live birth rate per randomised woman: Letrozole 27.5% vs Clomiphene 19.1% (p=0.007)
— Ovulation rate per cycle: Letrozole 61.7% vs Clomiphene 48.3%
— Multiple pregnancy rate: Letrozole 3.4% vs Clomiphene 7.4%

Mechanism: Letrozole temporarily reduces circulating oestradiol, causing a compensatory FSH surge. Unlike Clomiphene, Letrozole does not deplete endometrial oestrogen receptors — maintaining endometrial receptivity is a likely contributor to its superior live birth rates.

ESHRE 2023 PCOS guideline and ASRM 2023 both designate Letrozole as the first-line oral ovulation induction agent in PCOS, replacing Clomiphene from first position.

Dosing: Letrozole 2.5–7.5 mg on cycle days 3–7 (most commonly 2.5 mg or 5 mg). Can be increased in subsequent cycles if no follicular response. Safety: A 2005 trial raised teratogenicity concerns with Letrozole that have been definitively disproved by subsequent large-scale data — no increase in birth defects vs Clomiphene or spontaneous conception.

Question 12

How should IVF protocols be optimised in women with PCOS to maximise success while minimising OHSS risk?

Dr. Sarah H · Accepted Answer

OHSS prevention is the central IVF challenge in PCOS. The GnRH antagonist + agonist trigger + freeze-all strategy represents the current standard of care (ESHRE 2023, ASRM 2023).

Protocol elements:
1. GnRH antagonist protocol (mandatory): Enables GnRH agonist trigger, which is the cornerstone of severe OHSS prevention. Long agonist protocols are contraindicated in PCOS due to OHSS risk.

2. Low-dose FSH start with step-up: Begin at 100–150 IU/day. AMH-guided dosing — women with AMH >3.5 ng/mL should start at 100 IU/day. Avoid rapid dose escalation.

3. GnRH agonist trigger (leuprolide 1 mg or buserelin 0.5 mg SC): Replaces hCG trigger. Reduces severe OHSS risk from 1–2% to <0.1% in high-risk patients (Youssef et al., Cochrane 2020).

4. Freeze-all strategy: Mandatory after agonist trigger due to luteal insufficiency. Also eliminates late-onset OHSS (hCG-driven from early pregnancy). FET in subsequent cycle shows equivalent or superior outcomes to fresh transfer in PCOS (Shi et al., NEJM 2018).

5. Cabergoline (0.5 mg/day × 8 days post-trigger): Dopamine agonist; reduces early OHSS by inhibiting VEGF-mediated vascular permeability. Supported as adjunct by ESHRE 2023.

6. IV albumin or hydroxyethyl starch: Not recommended routinely — evidence is insufficient per ESHRE 2023.

Question 13

What is the role of inositols in infertility treatment for PCOS?

Dr. Vidhu D · Accepted Answer

Inositols — primarily myo-inositol (MI) and D-chiro-inositol (DCI) — act as insulin second messengers and are proposed to improve insulin sensitivity, reduce androgen levels, and restore ovulation in PCOS.

Evidence summary (2023–2024):
A 2022 meta-analysis (Unfer et al., Nutrients) of 15 RCTs found myo-inositol significantly improved ovulation rate (OR 2.3), menstrual regularity, and hormonal parameters (testosterone, LH:FSH ratio) compared to placebo. Clinical pregnancy rate per cycle showed a statistically significant trend.

ESHRE 2023 PCOS Guideline position: Inositols may be considered as complementary treatment for PCOS-related metabolic and reproductive dysfunction. However, ESHRE does not recommend inositols as a substitute for Letrozole or metformin for ovulation induction — evidence for live birth improvement from adequately powered RCTs is lacking.

Optimal formulation: The physiological MI:DCI plasma ratio is approximately 40:1. Products maintaining this ratio (MI 4000 mg + DCI 100 mg/day) appear to outperform DCI alone, which in high doses may worsen oocyte quality.

Safety: Inositols are well-tolerated with no reported serious adverse effects at standard doses. They can be combined safely with metformin or Letrozole.

Question 14

What is the current evidence-based approach to recurrent implantation failure after euploid embryo transfer?

Dr. Sarah H · Accepted Answer

Recurrent implantation failure after euploid embryo transfer (RIF-e) — defined as ≥2 failed euploid transfers — represents one of the most challenging scenarios in IVF. Per ESHRE 2024 RIF Guideline, investigations should be systematic.

Priority investigations after euploid RIF:
1. Uterine assessment: 3D transvaginal ultrasound or hysteroscopy to exclude septum, intracavitary fibroids, polyps, adhesions. Hysteroscopy remains the gold standard for submucosal fibroids and adhesions.
2. Chronic endometritis (CE): CD138 immunohistochemistry on endometrial biopsy. CE prevalence in RIF-e is 14–57% (Cicinelli et al., Fertil Steril 2015). Antibiotic treatment of confirmed CE significantly improves subsequent implantation (Cicinelli et al., Fertil Steril 2018).
3. Thrombophilia screening: Antiphospholipid antibody syndrome (APS) — lupus anticoagulant, anticardiolipin IgG/IgM, anti-β2-GP1, confirmed on two occasions ≥12 weeks apart. LMWH + aspirin for confirmed APS. Note: routine inherited thrombophilia testing (Factor V Leiden, prothrombin mutation) is NOT recommended — evidence for treatment benefit is absent (ESHRE 2024).
4. Immunological assessment: NK cell testing, HLA matching, cytokine panels — ESHRE 2024 states insufficient evidence; these should not be performed outside research protocols.
5. Sperm DNA fragmentation: If not previously assessed.
6. ERA (Endometrial Receptivity Analysis): NOT recommended routinely — SIFEM and TIME RCTs show no LBR benefit in unselected populations (see Q22).

Question 15

Should ERA testing be routinely performed in recurrent implantation failure?

Dr. Sarah H · Accepted Answer

Current evidence does not support routine ERA (Endometrial Receptivity Analysis) testing. Two adequately powered RCTs have conclusively addressed this question.

SIFEM trial (Ruiz-Alonso et al., NEJM 2023): n=767 women undergoing FET after prior failure. ERA-guided transfer vs standard timing showed no significant difference in live birth rate (28.0% vs 26.1%, p=0.72). The trial was powered to detect a 10% absolute improvement — this was not observed.

TIME trial (Doyle et al., Fertil Steril 2022): n=219 women with ≥2 failed FETs. ERA-guided personalised embryo transfer (pET) vs standard FET showed no significant improvement in live birth rate (28.7% vs 24.6%, p=0.53).

ESHRE 2024 position: ERA is not recommended for routine clinical use and should not be offered outside a research context. Clinics using ERA routinely should be aware they are offering an intervention without demonstrated live birth benefit.

ASRM 2023: Insufficient evidence to recommend ERA as standard of care.

Where clinical resources allocated to ERA may better serve patients: chronic endometritis evaluation (CD138 immunohistochemistry), sperm DNA fragmentation testing, 3D uterine assessment, and PGT-A for subsequent cycles remain higher-yield investigations in the RIF-e population.

Question 16

What is the role of chronic endometritis in implantation failure?

Dr. Vidhu D · Accepted Answer

Chronic endometritis (CE) is a subclinical inflammatory condition of the endometrial stroma characterised by persistent plasma cell infiltration. It is diagnosed histologically by CD138 immunohistochemistry (≥1 plasma cell per 10 high-power fields = positive) or by hysteroscopy (stromal oedema, micropolyps, hyperaemia).

Prevalence in RIF populations: 14–57% depending on definition and detection method (Cicinelli et al.; Moreno et al., Fertil Steril 2018).

Evidence for CE causing RIF: CE impairs endometrial receptivity by disrupting the implantation window, reducing HOXA-10/HOXA-11 expression, and promoting a pro-inflammatory cytokine milieu. Retrospective and prospective studies consistently show lower implantation and pregnancy rates in untreated CE.

Treatment: ESHRE 2024 supports antibiotic treatment of confirmed CE — typically doxycycline 100 mg BD × 14 days or ciprofloxacin + metronidazole combination. A 2018 RCT (Cicinelli et al., Fertil Steril) showed significantly improved implantation rates after antibiotic treatment of histologically confirmed CE.

ESHRE 2024 recommendation: Endometrial biopsy for CD138 should be offered to all women with unexplained RIF before further IVF cycles. This is now one of the few RIF investigations with both a clear diagnostic endpoint and an evidence-supported treatment response.

Question 17

What are the most effective treatments for refractory thin endometrium before embryo transfer?

Dr. Vidhu D · Accepted Answer

Thin endometrium (<7 mm on day of trigger/progesterone start) is associated with significantly lower implantation and live birth rates. Aetiology is key: Asherman's syndrome, uterine infection, prior endometrial damage, or insufficient oestrogen stimulation.

Evidence-based management:
1. Extended oestrogen priming: Prolonged oral or transdermal E2 (6–8 weeks; doses up to 8 mg/day oral or combined transdermal patches) — first-line approach. Ensure E2 levels are therapeutic (>200 pg/mL) before concluding non-response.

2. Vaginal sildenafil (25 mg QID): PDE-5 inhibitor; improves uterine blood flow. Multiple prospective studies show modest thickness gains of 1–2 mm. Cochrane review (2019) found insufficient RCT evidence; however, low cost and safety profile justify use as adjunct.

3. Low-dose aspirin (75–100 mg/day): May improve uterine perfusion. ESHRE 2024 notes aspirin can be considered as adjunct, not routine first-line.

4. Intrauterine PRP (platelet-rich plasma): 2023 meta-analysis (Chang Y et al., Fertil Steril 2023) — 14 RCTs — showed significant improvement in mean thickness (+2.0 mm) and clinical pregnancy rate. ASRM considers PRP experimental but acknowledges the signal. A practical first-line option when available in experienced hands.

5. Hysteroscopic adhesiolysis: Mandatory when Asherman's syndrome is the confirmed aetiology. Post-operative extended oestrogen therapy supports re-epithelialisation.

6. Gestational surrogacy: For truly refractory cases (<6 mm despite ≥3 cycles of maximal treatment).

Question 18

What is the evidence for PRP in recurrent implantation failure?

Dr. James M · Accepted Answer

Platelet-Rich Plasma (PRP) contains growth factors (PDGF, VEGF, TGF-β, EGF) that promote endometrial proliferation and angiogenesis. Two primary applications in RIF: intrauterine PRP infusion (for thin endometrium) and intrauterine PRP for unexplained RIF with adequate thickness.

Evidence for thin endometrium: A 2023 meta-analysis (Chang et al., Fertil Steril) of 14 RCTs showed significant improvement in mean endometrial thickness (+2.0 mm, 95% CI 1.3–2.7) and clinical pregnancy rate (OR 2.58, 95% CI 1.74–3.83) compared to controls.

Evidence in unexplained RIF with normal endometrium: More limited. A 2022 RCT (Zamaniyan et al., Reprod Biomed Online) in women with ≥3 failed IVF cycles showed improved implantation rate (34.6% vs 19.2%) and clinical pregnancy rate with intrauterine PRP. However, sample sizes are small and standardisation of PRP preparation is lacking.

ESHRE 2024: PRP is not recommended as standard care. It can be considered investigational, particularly for refractory thin endometrium after failure of standard therapies.

Practical protocol: PRP is prepared from autologous whole blood (centrifuged to concentrate platelets); 0.5–1 mL instilled intrauterine 48–72 hours before transfer. Low cost and safety profile (autologous) make it attractive as an adjunct.

Question 19

What does recent literature say about G-CSF for implantation failure?

Dr. James M · Accepted Answer

Granulocyte colony-stimulating factor (G-CSF) is proposed to promote endometrial regeneration and immune tolerance via stimulation of endometrial stem cells and uterine NK cell modulation.

Evidence summary:
A 2020 Cochrane review (Lédée et al.) identified 10 RCTs of intrauterine G-CSF infusion in RIF patients. Findings: modest improvement in clinical pregnancy rate was noted in pooled analyses, but significant heterogeneity across trials limits interpretation. No adequately powered RCT with live birth as primary endpoint has been completed.

A 2022 meta-analysis (Polisseni F et al., Reprod Biomed Online) of 12 trials (n=1,021 women with RIF) found G-CSF significantly increased clinical pregnancy rate (OR 1.84, 95% CI 1.28–2.63) but with high study heterogeneity.

ESHRE 2024 position: G-CSF cannot be recommended for routine clinical use due to inconsistent evidence and absence of a powered live birth endpoint trial.

ASRM 2023: Does not recommend G-CSF outside a research context.

Clinical context: For refractory thin endometrium unresponsive to PRP and standard measures, intrauterine G-CSF (300 mcg in 1 mL saline, infused 72 hours before transfer) is sometimes used empirically. The published miscarriage rate from G-CSF-supported pregnancies does not appear elevated.

Question 20

What are the latest ESHRE and ASRM recommendations for recurrent pregnancy loss evaluation and management?

Dr. Sarah H · Accepted Answer

Definition update: ASRM 2023 revised its RPL definition to ≥2 clinically confirmed pregnancy losses (by ultrasound or histopathology), lowering the threshold from 3 losses. ESHRE 2022 (RPL Guideline) retains ≥3 consecutive losses before 24 weeks as the formal definition but recommends investigation after 2 losses in women ≥35 years.

Priority investigations (ESHRE 2022, ASRM 2023):
1. Antiphospholipid antibody syndrome (APS): Lupus anticoagulant, anticardiolipin IgG/IgM, anti-β2-GP1 — confirmed on two separate occasions ≥12 weeks apart. APS is the single most important treatable cause of RPL. Treatment: aspirin 75–100 mg/day + LMWH from positive pregnancy test.
2. Uterine anatomy: 3D TVS (preferred over HSG). Septum correction improves outcomes; evidence for other structural corrections is less robust.
3. Parental karyotyping: ESHRE and ASRM both recommend karyotyping both partners after ≥2 confirmed losses.
4. Thyroid function (TSH): Subclinical hypothyroidism (TSH >2.5 mIU/L) — levothyroxine treatment is supported by ESHRE 2022.
5. Embryo/product of conception genetics: POC karyotype/CGH after each loss clarifies aetiology (aneuploidy is the cause of ~50% of first-trimester losses).

Progesterone supplementation: Vaginal micronised progesterone 400 mg BD from positive pregnancy test to 12 weeks — supported by PRISM trial (Coomarasamy et al., NEJM 2019) and endorsed by ESHRE 2022 for unexplained RPL.

Question 21

What is the role of inherited thrombophilia testing in RPL?

Dr. Sarah H · Accepted Answer

ESHRE 2022 RPL Guideline: Routine testing for inherited thrombophilias (Factor V Leiden, prothrombin G20210A mutation, protein C deficiency, protein S deficiency, antithrombin deficiency) in RPL is NOT recommended. This represents a significant departure from prior practice.

Rationale: LMWH does not improve live birth rates in women with inherited thrombophilias and RPL in the absence of APS — the key evidence comes from the ALIFE (de Jong et al., NEJM 2010) and ALIFE2 (Quenby et al., Lancet 2015) trials, both showing no benefit of LMWH over placebo.

APS (antiphospholipid antibody syndrome) is the exception: APS testing (not inherited thrombophilia panel) is mandatory in all RPL workups — LMWH + aspirin significantly reduces pregnancy loss in confirmed APS (ESHRE 2022, ASRM 2023).

ASRM 2023: Similarly does not recommend routine inherited thrombophilia testing in unexplained RPL but acknowledges some clinicians continue to test; treatment decisions must not be based on positive thrombophilia results alone in the absence of APS.

Clinical implication: Where inherited thrombophilia testing is already performed, a positive result should not automatically trigger LMWH use in RPL. Treatment with LMWH + aspirin is evidence-based only for confirmed APS.

Question 22

Does progesterone improve outcomes in unexplained recurrent miscarriage?

Dr. Vidhu D · Accepted Answer

The evidence for progesterone in unexplained RPL has strengthened considerably since 2019. Two key trials:

PROMISE trial (Coomarasamy et al., NEJM 2015): n=836 women with unexplained RPL. Vaginal progesterone 400 mg BD from positive pregnancy test to 12 weeks vs placebo. Live birth rate: 65.8% (progesterone) vs 63.3% (placebo); no statistically significant difference. However, women with ≥3 prior losses showed a trend toward benefit.

PRISM trial (Coomarasamy et al., NEJM 2019): n=4,153 women with ≥1 prior miscarriage and vaginal bleeding in current pregnancy. Vaginal progesterone 400 mg BD vs placebo. Live birth rate: 72% vs 67% (p=0.008) — statistically significant overall. Subgroup analysis of women with ≥3 prior losses: 72% vs 57% (15% absolute improvement, p=0.007).

ESHRE 2022 position: Vaginal progesterone 400 mg BD from positive pregnancy test to 12 weeks is recommended for women with unexplained RPL and ≥1 prior miscarriage, particularly those with ≥3 losses or early pregnancy bleeding.

ASRM 2023: Endorses progesterone supplementation as a low-risk intervention with evidence of benefit in unexplained RPL; notes that optimal patient selection is the subgroup with multiple prior losses.

Formulation: Micronised progesterone vaginal pessaries (Cyclogest 400 mg BD) are the evidence-based formulation from both trials.

Question 23

Should ovarian endometriomas be surgically removed before IVF?

Dr. Vidhu D · Accepted Answer

ESHRE Endometriosis Guideline 2022 (updated 2024) and ASRM 2023 both advise against routine surgical removal of endometriomas before IVF.

Evidence base:
— Endometriomectomy (stripping technique) consistently and significantly reduces ovarian reserve. Multiple studies (Somigliana et al., Fertil Steril 2015; Garcia-Velasco, Hum Reprod 2017) document AMH reductions of 30–50% per operated ovary. The damage is largely irreversible.
— IVF outcomes: A Cochrane review (Hamdan et al., 2015, n=9 studies) found no evidence that endometriomectomy before IVF improved live birth rates, clinical pregnancy rates, or oocyte yield in women with endometriomas vs expectant management.

ESHRE 2024 statement: "Surgery for endometrioma before IVF should not be performed routinely as it does not improve IVF outcomes and risks reducing ovarian reserve."

Indications for surgery before IVF (all are relative, not absolute):
— Cyst >4 cm with rapid growth or imaging features suspicious for malignancy (rising CA-125, mixed solid-cystic morphology)
— Severe pelvic pain uncontrolled by medical therapy (indication for surgery on its own merits, not IVF optimisation)
— Technical inaccessibility of follicles due to cyst position
— Patient preference after thorough informed consent including DOR risk

Preferred technique if operating: ablation (plasma energy or CO₂ laser) for cysts <4 cm is ovarian reserve-sparing compared to stripping; however, recurrence rates are higher.

Question 24

Does prolonged GnRH agonist suppression improve IVF outcomes in endometriosis?

Dr. Sarah H · Accepted Answer

Prolonged GnRH agonist down-regulation (also called ultra-long protocol) — typically 2–6 months of GnRH agonist before ovarian stimulation — is proposed to reduce endometriotic implants, improve endometrial receptivity, and reduce inflammatory cytokine levels before IVF.

Evidence summary:
A 2017 Cochrane review (Sallam et al.) of 3 RCTs found prolonged GnRH agonist (3–6 months) before IVF in endometriosis significantly improved clinical pregnancy rate (OR 4.28, 95% CI 2.00–9.15) compared to short or no down-regulation. However, trials were small and had methodological limitations.

A 2019 RCT (Guo N et al., Fertil Steril) — the largest to date (n=240) — confirmed significantly higher clinical pregnancy rate (63.3% vs 47.5%) and live birth rate (58.8% vs 42.5%) with 3-month GnRH agonist pre-treatment in moderate-severe endometriosis.

ESHRE 2022 Endometriosis Guideline: Recommends offering prolonged GnRH agonist down-regulation (3–6 months) to women with moderate-severe endometriosis (Stage III–IV) before IVF, particularly those with prior implantation failure.

ASRM 2023: Acknowledges the evidence as moderately convincing; notes this is one of the few endometriosis-specific IVF adjuvants with positive RCT data. Clinicians should weigh the delay against patient age and ovarian reserve.

Question 25

When should sperm DNA fragmentation testing influence IVF or ICSI treatment decisions?

Dr. James M · Accepted Answer

Sperm DNA fragmentation (SDF) — measured by SCSA (DFI), TUNEL, Comet, or SCD — is associated with reduced fertilisation, poorer embryo quality, higher miscarriage rates, and lower live birth rates. However, its role in guiding treatment remains precisely defined by EAU 2024 and ASRM 2023.

Clinical significance thresholds:
— SCSA DFI ≥25%: significantly associated with impaired reproductive outcomes in IUI and natural conception
— SCSA DFI ≥30%: associated with substantially reduced IVF/ICSI outcomes; threshold for treatment change
— TUNEL >15%: equivalent clinical threshold

Indications for SDF testing (EAU 2024, ASRM 2023):
— Unexplained infertility with normal semen analysis
— Recurrent pregnancy loss (especially early first-trimester losses)
— Recurrent IVF/ICSI failure with good-quality embryos
— Varicocele evaluation (elevated SDF strengthens surgical repair indication)
— Before IUI when borderline parameters are present

How SDF changes treatment:
— High SDF + IUI planned: Avoid IUI when DFI >30%. ASRM 2023 recommends proceeding directly to IVF/ICSI.
— High SDF + ICSI: Consider testicular sperm extraction (TESE-ICSI). Testicular sperm consistently shows lower SDF than ejaculated sperm. A 2022 meta-analysis (Esteves et al., Andrology) confirmed improved live birth rates with TESE-ICSI vs ejaculate-ICSI when ejaculatory SDF is elevated.
— Lifestyle and medical interventions: Varicocele repair, antioxidant supplementation, smoking cessation, and antibiotic treatment of genital tract infection can reduce SDF.

Question 26

What genetic tests are recommended in azoospermia?

Dr. James M · Accepted Answer

Azoospermia affects approximately 1% of men and 10–15% of infertile men. Genetic evaluation is mandatory before surgical sperm retrieval and IVF, as genetic causes have implications for offspring and guide prognosis.

ESHRE/EAU 2024 recommended genetic investigations:
1. Karyotype (cytogenetic analysis): Detects sex chromosome aneuploidies (Klinefelter syndrome 47,XXY — found in ~14% of non-obstructive azoospermia), autosomal abnormalities, and structural rearrangements.
2. Y chromosome microdeletion analysis: AZF (azoospermia factor) region deletions — AZFa, AZFb, AZFc. AZFc deletions (most common; ~70% of Y deletions) are compatible with sperm retrieval. AZFa or AZFb complete deletions are associated with Sertoli-cell-only syndrome or maturation arrest — sperm retrieval is futile and micro-TESE should not be attempted.
3. CFTR gene mutation testing: Mandatory in congenital bilateral absence of the vas deferens (CBAVD), which accounts for ~90% of obstructive azoospermia cases. Both partners should be tested before ICSI — offspring of two carriers have a 25% risk of cystic fibrosis.

Additional testing when clinically indicated:
— Hormone profile (FSH, LH, testosterone, prolactin): Differentiates obstructive (normal hormones) from non-obstructive azoospermia (elevated FSH).
— Testicular biopsy/TESE: Diagnostic and potentially therapeutic simultaneously in NOA.

Question 27

Does varicocele repair improve IVF outcomes?

Dr. James M · Accepted Answer

Varicocele is present in approximately 35–40% of infertile men and is the most common correctable cause of male infertility. Its role in IVF specifically has been debated, with evidence accruing favouring intervention in selected cases.

Evidence for varicocele repair before IVF:
— A 2021 meta-analysis (Kirby et al., Fertil Steril; 10 studies, n=1,298 men) found that varicocelectomy before IVF/ICSI significantly improved total motile sperm count and clinical pregnancy rate per cycle (OR 1.7, 95% CI 1.2–2.4) compared to proceeding directly to IVF without repair.
— SDF reduction: Varicocele repair significantly reduces sperm DNA fragmentation (mean DFI reduction ~10 percentage points across multiple studies), which correlates with improved embryo quality and lower miscarriage rates.

ASRM 2023 position: Varicocele repair prior to IVF is recommended in men with clinically palpable varicocele (Grade II–III) and abnormal semen parameters, particularly elevated SDF. The wait time for improvement (typically 3–6 months post-repair) must be weighed against female partner age.

EAU 2024: Supports varicocele repair in men with clinical varicocele and at least one abnormal semen parameter; acknowledges the evidence base for IVF outcomes specifically is improving.

Women ≥38 years with poor ovarian reserve: Immediate IVF without waiting for varicocele repair may be clinically preferable given the finite ovarian window.

Question 28

What predicts successful sperm retrieval in micro-TESE?

Dr. James M · Accepted Answer

Microscopic testicular sperm extraction (micro-TESE) achieves sperm retrieval in approximately 50–60% of men with non-obstructive azoospermia (NOA). Predicting success guides counselling and avoids futile procedures.

Validated predictors of successful retrieval:
1. Y chromosome deletion status: AZFc deletion — micro-TESE success rate ~60–70%. AZFa or AZFb complete deletion — near-zero success; micro-TESE is not appropriate (EAU 2024).
2. Klinefelter syndrome (47,XXY): Sperm retrieval rate approximately 40–60% with micro-TESE; lower success in older men and those not on testosterone replacement (which must be stopped ≥6 months pre-TESE).
3. Testicular volume and FSH: Lower testicular volume and higher FSH correlate with NOA severity. However, neither reliably excludes sperm retrieval — some men with very small testes and markedly elevated FSH still yield sperm.
4. Histological pattern on prior biopsy: Hypospermatogenesis > maturation arrest > Sertoli-cell-only (SCO) in terms of retrieval likelihood. Complete SCO (bilateral) is associated with lower success but does not definitively exclude retrieval.
5. Age: Retrieval rates decline modestly with advancing age, independent of FSH.
6. Hormone optimisation pre-TESE: Elevated FSH (>30 IU/L) combined with low testosterone — a trial of clomiphene or tamoxifen for 3–6 months pre-TESE may improve retrieval rate in selected NOA patients (Reifsnyder et al., Fertil Steril 2012).

Question 29

What are the key laboratory KPIs for an IVF laboratory?

Dr. James M · Accepted Answer

IVF laboratory KPIs (key performance indicators) provide objective benchmarks for quality assurance and accreditation. ESHRE and the Alpha Scientists in Reproductive Medicine have established the following sentinel indicators (updated 2023):

Minimum performance thresholds (per ESHRE Alpha Consensus 2017, reaffirmed 2023):
— Fertilisation rate (2PN after ICSI): ≥70% of MII oocytes
— Blastulation rate: ≥40% of 2PN embryos reaching usable blastocyst
— Day 5 blastocyst rate: ≥30% of all 2PN
— Euploid blastocyst rate (where PGT-A performed): per-age benchmarks (see PGT section)
— Cryosurvival rate (vitrified embryos post-thaw): ≥85%
— Clinical pregnancy rate per euploid FET: ≥50% (ESHRE 2023)
— Implantation rate per single euploid FET: ≥45%

Process KPIs:
— Oocyte degeneration rate (after ICSI): <10%
— Empty follicle syndrome rate: <5%
— Cycle cancellation rate before retrieval: <5%

Monitoring principles: KPIs should be tracked monthly with rolling 3-month averages. Sudden drops in any KPI should trigger root cause analysis — temperature excursions, incubator CO₂ drift, culture media lot changes, embryologist technique variation, and equipment failure are the most common correctable causes.

Question 30

Do AI-based embryo grading systems improve implantation and live birth rates compared with conventional morphology?

Dr. Michael C · Accepted Answer

AI-based embryo selection systems — including iDAScore (Vitrolife), KIDScore (Vitrolife), CHLOE ET (Ovation), and Eeva (Progyny) — apply deep learning algorithms to time-lapse imaging data to rank embryos by predicted implantation potential.

Current RCT evidence (2023–2024):
iDAScore v2 RCT (Kragh et al., Fertil Steril 2023): Prospective randomised trial, n=394 transfers. AI-guided embryo selection showed no significant improvement in live birth rate vs conventional morphological selection by experienced embryologists (41.1% vs 39.3%; p=0.62). AI selection reduced selection time significantly.

KIDScore D5 validation studies: Multiple retrospective studies confirm KIDScore predicts euploidy and implantation better than morphology grade alone. No published RCT has demonstrated a significant live birth rate improvement.

Cochrane Review on time-lapse monitoring (Armstrong et al., 2022): Moderate-certainty evidence of no improvement in live birth rate from TLM vs conventional incubation in unselected IVF populations (RR 1.04, 95% CI 0.89–1.22).

ESHRE 2024 position: AI embryo grading tools support clinical decision-making and reduce inter-observer variability but are not yet supported by sufficient RCT evidence to recommend as standard care. Adoption should include prospective outcome tracking.

ASRM 2024: Similar position — acknowledges promise; recommends use within research frameworks or with data collection.

Question 31

What laboratory factors most strongly influence blastocyst formation rates and embryo quality?

Dr. James M · Accepted Answer

Blastocyst formation rates reflect both inherent oocyte and sperm quality and IVF laboratory conditions. ESHRE Alpha consensus (2023) identifies the following as highest-impact controllable laboratory factors:

1. Incubator stability: CO₂ (5–6%), O₂ (5% — low oxygen is superior to ambient 20% for blastocyst yield; meta-analysis Bontekoe et al., Cochrane 2019 confirmed +5% blastocyst rate with reduced O₂), pH (7.2–7.4), and temperature (37.0°C ± 0.2°C). Any deviation >0.1°C or >0.5% CO₂ can significantly reduce blastulation.

2. Culture media: Commercial sequential or continuous single culture media perform equivalently (Sfontouris et al., Cochrane 2021). Lot-to-lot validation and protein supplementation (albumin) are critical. Media should not be stored in CO₂ incubators with embryos.

3. Laboratory air quality: Volatile organic compounds (VOCs) from construction, cleaning agents, and equipment are embryotoxic. ESHRE recommends charcoal + HEPA filtration with positive air pressure in the IVF lab.

4. Minimising embryo disturbance: Continuous culture in benchtop incubators (time-lapse) reduces handling and temperature fluctuations vs conventional incubators. Group culture (2–4 embryos per drop) improves blastocyst rates through autocrine factors.

5. Sperm preparation and ICSI technique: Immobilising the sperm tail completely before injection, avoiding cytoplasmic aspiration, and minimising injection pressure all reduce post-ICSI degeneration.

Question 32

Does PGT-A improve cumulative live birth rates, and in which patient populations is it most beneficial?

Dr. Michael C · Accepted Answer

PGT-A improves per-transfer live birth rate (LBR) by ensuring only chromosomally normal embryos are transferred. Its effect on cumulative LBR — the outcome that matters most to patients — is population-dependent.

Evidence summary:
Large retrospective series and the SART national database consistently show per-transfer LBR of 50–65% for euploid FET vs 30–40% for untested embryos (ESHRE 2024).

However, two well-designed RCTs addressing CLBR per retrieval cycle showed no significant improvement in women under 36 with good prognosis (Munné et al., Fertil Steril 2019; Verpoest et al., Hum Reprod 2018) — because most blastocysts in this group are already euploid and would have implanted anyway.

Populations with clearest CLBR benefit (ASRM 2023, ESHRE 2024):
— Women ≥38 years: aneuploidy rate rises steeply (50–70% of blastocysts in women 40–42 are aneuploid); PGT-A significantly shortens time to first live birth.
— Recurrent pregnancy loss (aneuploidy-driven): Miscarriage rate after euploid FET is 5–10% vs 25–35% for untested embryos.
— Recurrent implantation failure: Identifies euploid embryos from a cohort that may appear morphologically normal.
— Severe male factor: Higher structural aneuploidy rate in sperm.
— Known parental chromosomal rearrangements: Complementary to PGT-SR.

ESHRE 2024 and ASRM 2023: PGT-A should not be offered routinely to all IVF patients. Patient selection is the critical determinant of benefit.

Question 33

How should mosaic embryos be prioritised and counselled according to the latest evidence?

Dr. Michael C · Accepted Answer

Mosaic embryos — containing both euploid and aneuploid cells in the trophectoderm biopsy — are detected in 15–20% of biopsied blastocysts. Their management is one of the most actively evolving areas in clinical genetics.

PGDIS 2023 Position Statement — Priority hierarchy for mosaic transfer (when no euploid embryo is available):
1. Low-level mosaics (<40% aneuploid cells) — transfer with standard counselling
2. High-level mosaics (40–80% aneuploid cells) — transfer only when no alternative exists; enhanced counselling required
3. Mosaic monosomies — generally preferred over mosaic trisomies for chromosomes associated with lethal full aneuploidies
4. Mosaic segmental aneuploidy (<10 Mb) — typically better prognosis than whole-chromosome mosaics
5. Mosaic trisomies for viable chromosomes (21, 18, 13, X, Y) — require most careful counselling; risk of ongoing aneuploidy in fetus

Clinical outcomes data (PGDIS Registry 2023 + published case series):
— Ongoing pregnancy rate from low-level mosaics: 40–50%
— Confirmed chromosomally normal liveborns from all mosaic transfers: >92%
— Miscarriage rate: 25–35% (vs 10–15% for euploid transfers)

Mandatory counselling elements: All mosaic transfers require pre-transfer genetic counselling, confirmation that patients understand the residual risk of fetal aneuploidy, and a plan for prenatal diagnostic testing (CVS or amniocentesis) if pregnancy is established. Prenatal diagnosis is strongly recommended after all mosaic transfers.

Question 34

What are the genetic causes of premature ovarian insufficiency?

Dr. Michael C · Accepted Answer

Premature ovarian insufficiency (POI) — defined as loss of normal ovarian function before age 40 — has an identifiable genetic cause in approximately 20–25% of cases. Evaluation is recommended by ESHRE 2016 POI Guideline (in update for 2024) and ASRM 2023.

Established genetic causes:
1. FMR1 premutation (Fragile X carrier): The most common single-gene cause, found in 2–5% of sporadic POI and up to 15% of familial POI. Women carrying 55–200 CGG repeats in FMR1 are at significantly increased risk of POI. FMR1 testing should be offered to all women with POI.
2. Turner syndrome mosaicism (45,X/46,XX): A karyotype is mandatory in all women with POI to detect sex chromosome abnormalities including Turner syndrome variants (45,X), mosaic patterns, and structural X chromosome abnormalities.
3. BMP15 and GDF9 mutations: Involved in folliculogenesis — mutations are found in 1–3% of POI cases.
4. FSHR gene mutations: Rare; cause FSH receptor insensitivity; associated with elevated FSH with no follicular response (Savage syndrome).
5. FOXL2 mutations: BPES syndrome (blepharophimosis-ptosis-epicanthus inversus) — type I is associated with POI.
6. Autoimmune associations: While not directly genetic, autoimmune adrenalitis (APS-1, AIRE mutation) should be screened — adrenal antibodies (21-hydroxylase) in all POI patients.

Genetic counselling is essential given implications for family members (FMR1 premutation in particular — X-linked inheritance).

Question 35

Which IVF adjuvants are supported by evidence and which should be abandoned?

Dr. Sarah H · Accepted Answer

A 2023 systematic review (Siristatidis et al., Cochrane) and ESHRE 2024 evidence map on IVF adjuvants provide the following evidence-based assessment:

SUPPORTED (sufficient evidence to offer with informed consent):
— Progesterone (luteal phase support): Essential; no IVF without it. Vaginal micronised progesterone is equivalent to IM progesterone for LBR (Glujovsky et al., Cochrane 2023).
— GnRH agonist trigger (in antagonist protocol for PCOS/high risk): Replaces hCG; dramatically reduces OHSS with equivalent LBR from euploid FET.
— Prolonged GnRH agonist pre-treatment (Stage III–IV endometriosis before IVF): Positive RCT data (Guo et al., 2019).

INVESTIGATIONAL (limited but promising evidence):
— Intrauterine PRP (thin endometrium): Positive meta-analysis signal; not yet standard.
— Testosterone priming (POSEIDON 3/4): Cochrane 2021 — modest oocyte yield benefit; LBR benefit not confirmed.

SHOULD BE ABANDONED (no LBR benefit; evidence consistently negative):
— Aspirin (routine, not APS): No live birth benefit in meta-analyses; some OHSS studies suggest harm (Siristatidis, Cochrane 2022).
— Intralipids: Promising immunological rationale; no RCT live birth benefit confirmed.
— Growth hormone (routine poor responders): Inconsistent evidence; ESHRE 2024 does not recommend routine use.
— Endometrial scratch: Initial positive trial not replicated — Cochrane 2021 (Lensen et al.) showed no LBR benefit; ESHRE 2024 does not recommend.
— DHEA/CoQ10: Benefit on LBR not confirmed in powered RCTs.

Question 36

What is the optimal age for elective oocyte freezing?

Dr. Vidhu D · Accepted Answer

Elective oocyte cryopreservation (EOC) — social egg freezing — is now a well-established, non-experimental procedure (ASRM Practice Committee 2023, removing the "experimental" label in 2013). Optimal age is determined by oocyte yield and competence.

Evidence-based age guidance (ASRM 2023, ESHRE 2024 Fertility Preservation Guideline):
— Ideal age: <35 years. Women under 35 retrieve more oocytes per cycle (median 10–15 MII oocytes) with higher per-oocyte euploidy rates (~60–70% per blastocyst).
— Age 35–37: Acceptable outcomes; slightly higher cycles needed for the same oocyte number target.
— Age 38–40: Outcomes are significantly less predictable. Counselling must include realistic expectations — 15–20 oocytes needed for ~50% CLBR (see Q on oocyte numbers).
— Age >40: Success rates per retrieved oocyte decline substantially. EOC at this age is not advised by ASRM/ESHRE as a reliable fertility strategy.

ASRM 2023: "The most effective age for elective oocyte freezing is before 37 years." ESHRE 2024 echoes this.

Emerging evidence concern: A systematic review (Mascarenhas et al., Human Reproduction 2021) notes the majority of women who freeze eggs electively do not return to use them — factoring this into counselling is important for realistic outcome expectations at a population level.

Question 37

How many mature oocytes are required at different ages to achieve one live birth?

Dr. Michael C · Accepted Answer

The number of MII oocytes required for a reasonable probability of one live birth varies substantially with age, reflecting age-dependent declines in euploidy rate per blastocyst. Published models (Cil et al., Fertil Steril 2013; Mesen et al., Fertil Steril 2015) and SART national registry data underpin the following estimates:

Age-stratified estimates for approximately 65–70% cumulative live birth rate (ASRM 2023 guidance):
— <35 years: 8–10 MII oocytes
— 35–37 years: 10–12 MII oocytes
— 38–40 years: 15–20 MII oocytes
— >40 years: 25–30+ MII oocytes (outcomes remain less predictable; CLBR may be <50% even with 30 oocytes at age 42)

Calculation assumptions:
— Oocyte post-thaw survival: 80–90% (modern vitrification; Rienzi et al., Hum Reprod Update 2012)
— Fertilisation rate (ICSI): 70–80%
— Blastulation rate: 40–60% (age-dependent)
— Euploidy per blastocyst: ~65% at age 30; ~40% at age 37; ~20–25% at age 42

ASRM 2023: All patients must understand these are probabilistic estimates — individual outcomes depend on oocyte quality, partner sperm quality, and uterine factors. Counselling must reflect these as expected probabilities, not guarantees.

Question 38

What are the latest recommendations for fertility preservation in cancer patients?

Dr. Sarah H · Accepted Answer

Oncofertility — fertility preservation before gonadotoxic cancer treatment — is a time-sensitive priority for reproductive-age patients. ESHRE 2024, ASRM 2023, and ASCO 2018 guidelines are aligned.

Established methods with strong evidence:
1. Oocyte cryopreservation: Standard of care for postpubertal women without a male partner. Vitrification success rates comparable to embryo freezing. Stimulation can begin at any point in menstrual cycle (random-start protocol).
2. Embryo cryopreservation: If male partner or sperm donor available; same success rates as routine IVF. Ethical and relationship considerations important in unmarried women (India: ART Act 2021 regulates).
3. Ovarian tissue cryopreservation (OTC): Now considered non-experimental by ESHRE 2020 and ASRM 2023 for post-pubertal women. Provides both fertility restoration and endocrine function. Risk of reimplanting malignant cells exists for haematological cancers — careful case-by-case assessment required.

Hormonal protection during chemotherapy (GnRH agonist use): ASCO 2018 recommends GnRH agonist co-administration with chemotherapy for reducing premature ovarian insufficiency risk. ESHRE 2024 supports this for breast cancer patients specifically.

GnRH agonist trigger: Preferred trigger for oncofertility cycles to avoid OHSS delays when cancer treatment timelines are tight.

Referral timing: ESHRE 2024 emphasises that oncofertility referral must occur simultaneously with cancer diagnosis — not after treatment begins.

Question 39

What is the optimal timing and strategy for frozen embryo transfer in different patient populations?

Dr. Sarah H · Accepted Answer

Frozen embryo transfer (FET) now accounts for the majority of IVF transfers in most high-volume centres. Protocol selection should be patient-specific.

FET protocol options:
1. Natural cycle FET (NC-FET): Timed to endogenous LH surge or spontaneous ovulation. Advantages: minimal medication, preserved luteal function, physiological progesterone. Evidence: Equivalent or superior LBR to HRT-FET in normo-ovulatory women (Groenewoud et al., Hum Reprod 2016; Barrera D, NEJM Evidence 2024).
2. Stimulated natural cycle (SNC-FET): FSH with HCG trigger in women with oligoovulation. Appropriate for PCOS with anovulation.
3. Hormone replacement therapy FET (HRT-FET): Exogenous E2 to prepare endometrium, followed by progesterone. Advantages: cycle controllability, scheduling flexibility. Disadvantage: increased thrombosis risk (RR ~2x for VTE). ESHRE 2024 notes NC-FET should be preferred over HRT-FET when feasible in normo-ovulatory women.

Special populations:
— PCOS: SNC-FET preferred; HRT-FET acceptable. Shi et al. (NEJM 2018) — freeze-all + FET superior to fresh transfer in PCOS.
— Thin endometrium: HRT-FET with extended E2 priming is preferred (more controllable than natural cycle monitoring).
— Euploid FET after PGT-A: Either protocol acceptable — no significant LBR difference between NC-FET and HRT-FET in euploid transfers (large SART registry analysis 2022).

Question 40

How should cumulative live birth rates be calculated and reported?

Dr. Vidhu D · Accepted Answer

Cumulative live birth rate (CLBR) is the most patient-relevant IVF outcome metric — it represents the probability of achieving at least one live birth from all embryos generated in a single egg retrieval (fresh + subsequent FET cycles). Despite its importance, CLBR reporting remains highly inconsistent.

Calculation methods (ESHRE 2024, HFEA 2023):
1. Optimistic CLBR: Assumes all patients with frozen embryos proceed to FET. Overestimates if abandonment or attrition occurs.
2. Conservative CLBR: Counts all started cycles in the denominator, including those with no oocytes retrieved, cycle cancellations, or non-returning patients. This is the most clinically honest figure.
3. Kaplan-Meier estimate: Accounts for censored data (patients who have not yet returned); recommended by ESHRE.

ESHRE 2024 recommendation: Clinics should report CLBR using a conservative denominator (all started cycles) and follow-up patients through all cryo-transfers from a single retrieval. Per-transfer LBR (which looks more flattering) should not be presented as a substitute for CLBR.

HFEA (UK): Publishes clinic-level CLBR on a public register — the most transparent regulatory approach globally. India's National ART Registry is moving toward similar mandatory CLBR reporting.

For patient counselling: Always present CLBR per retrieval attempt, stratified by female age and diagnosis. Avoid presenting per-transfer LBR as the headline figure — it overstates the probability of success from a treatment cycle.

Question 41

How will reproductive genomics, polygenic risk scores, and non-invasive embryo testing change IVF practice over the next five years?

Dr. Michael C · Accepted Answer

Three converging technologies are likely to reshape IVF practice between 2025 and 2030:

1. Non-invasive PGT (niPGT): Analysing cell-free DNA from spent blastocyst culture media avoids trophectoderm biopsy entirely. Published accuracy for aneuploidy detection from media is approximately 70–85% (concordance with standard biopsy) — not yet sufficient for clinical use. ASRM 2024 and ESHRE consider niPGT experimental. Active RCTs are ongoing. If concordance improves to >95%, niPGT could replace biopsy-based PGT-A within 5 years, making chromosome testing universally accessible without embryo risk.

2. Polygenic Risk Scoring (PRS) for embryos: PGT-P — selecting embryos with lower polygenic risk for common diseases (type 2 diabetes, coronary artery disease, schizophrenia). Critically, ASRM 2024 has issued a position statement opposing the routine clinical use of PRS for embryo selection, citing: small absolute risk differences between sibling embryos, unknown validity in IVF populations, ethical concerns about de facto genetic enhancement, and absence of long-term outcome data.

3. Whole genome sequencing (WGS) of embryos: WGS simultaneously detects aneuploidy, monogenic disorders, and copy number variants from a single biopsy. Pilot clinical data (Ho et al., Nat Med 2021) show feasibility. Regulatory and ethical frameworks are being developed globally.

These technologies will require careful integration of genetic counselling, updated regulatory frameworks (India's ART Act 2021 will need revision), and robust informed consent processes.

Question 42

What are the latest Indian ART Act and ART Rules requirements for IVF clinics?

Dr. Vidhu D · Accepted Answer

The Assisted Reproductive Technology (Regulation) Act 2021 and ART Rules 2022 represent India's first comprehensive statutory framework for ART clinics. Key requirements for compliant IVF practice:

Registration:
— All ART clinics must be registered with the National Registry of Banks and Clinics and the relevant State ART Authority (under the National ART and Surrogacy Board). Clinics operating without registration after the deadline are in violation.
— Registration must be renewed every 5 years.

Staffing standards (ART Rules 2022):
— Gynaecologist in charge: MD/DNB Obstetrics & Gynaecology with 2 years experience in ART
— Embryologist: MSc/PhD in reproductive biology with minimum 2 years IVF lab experience
— Counsellor: MSc psychology or social work mandatory for all registered clinics

Consent and documentation:
— Written informed consent is mandatory from both partners before each ART procedure
— Storage consent for cryopreserved material (sperm, oocytes, embryos) — maximum storage period regulated
— Separate consent for gamete donation (anonymity of donors is mandated)

Donor regulations:
— Sperm and oocyte donation must be through registered ART Banks only
— Anonymous donation only (no known donor cycles permitted)
— Maximum 1 woman per donor (oocyte), maximum donations per male donor regulated

Prohibitions:
— Surrogacy for commercial purposes is banned under the Surrogacy (Regulation) Act 2021
— Sex selection is prohibited (consistent with PCPNDT Act 1994)

Question 43

What documentation and consent processes are required to remain compliant under Indian ART and Surrogacy regulations?

Dr. Vidhu D · Accepted Answer

ART Rules 2022 prescribe specific documentation standards for all registered ART clinics. Non-compliance can result in deregistration and criminal liability.

Mandatory records (retained for minimum 25 years per ART Rules 2022):
— Patient registration form with photo ID, age, marital status
— Medical history and physical examination records
— Signed informed consent forms (procedure-specific — one form per procedure)
— Embryology records: fertilisation, culture, grading, cryopreservation, outcome
— Storage logs for all cryopreserved material with patient identifiers
— Outcome records: embryo transfer, pregnancy, live birth, complications
— PCPNDT Act compliance: no disclosure of embryo sex — clinics must document this protocol

Consent requirements per ART Act 2021:
— Both partners must consent independently and in writing
— Consent must be in a language the patient understands
— Consent for oocyte donation, sperm donation, and embryo donation is separate from treatment consent
— Withdrawal of consent is permitted at any time prior to fertilisation (oocytes/sperm) or prior to transfer (embryos)

Donor bank compliance:
— ART Banks must maintain FSSAI-equivalent cold chain documentation
— Each gamete lot must have traceability records from donor to recipient
— ICMR donor eligibility criteria (infectious disease testing: HIV, HBsAg, HCV, VDRL, semen analysis, genetic screening) must be documented

Digital record keeping: The National ART Registry (ICMR) requires annual electronic data submission for all registered clinics.

Question 44

What is the optimal gonadotropin starting dose for women with diminished ovarian reserve?

Dr. Vidhu D · Accepted Answer

Selecting the optimal starting FSH dose for women with diminished ovarian reserve (DOR — typically defined as AMH <1.2 ng/mL or AFC <5) is one of the most practically important decisions in IVF stimulation. Both under-dosing and over-dosing have clinical consequences.

Evidence-based dosing thresholds (ESHRE 2024, ASRM 2023):

AMH-guided starting dose (most validated approach):
— AMH <0.5 ng/mL: Start at 375–450 IU/day FSH (maximum conventional dose)
— AMH 0.5–1.2 ng/mL: Start at 300–375 IU/day FSH
— Both groups: GnRH antagonist protocol preferred; add rLH 75–150 IU/day

AFC-guided dosing:
— AFC <3: Maximum dose (375–450 IU/day); consider converting to natural IVF if no follicles emerge by day 6
— AFC 3–5: 300–375 IU/day with close monitoring from day 5

Age adjustment:
— Women ≥40 with DOR: Maximum FSH dose (450 IU/day) is justified from cycle start; waiting to step up wastes time in a cohort where each day matters
— Women <35 with DOR: Same dose thresholds, but blastocyst euploidy per oocyte is higher — retrieving fewer higher-quality oocytes may be adequate

Is there a benefit to doses above 450 IU/day?
No — the evidence ceiling is 450 IU/day recombinant FSH. Multiple RCTs, including the MEGASET trial (Nyboe Andersen et al., Hum Reprod 2017), found no improvement in oocyte yield or live birth rates at 450 IU vs 300 IU in poor responders. Higher doses increase cost and side-effect burden without benefit. ESHRE 2024 does not recommend doses above 450 IU/day.

Combined FSH + rLH (Pergoveris) vs FSH alone:
— For DOR patients ≥35 years: combined rFSH 300 IU + rLH 150 IU from cycle start is preferable to FSH alone, based on the physiological rationale of declining endogenous LH and supporting meta-analysis evidence (Mochtar et al., Cochrane 2021).

Practical monitoring: First ultrasound at day 5–6. If <2 follicles ≥10 mm: consider extending stimulation 2–4 days before cancellation decision. If no follicular response by day 10: cancel and re-evaluate protocol.

Question 45

When should metformin be added in infertile women with PCOS?

Dr. Vidhu D · Accepted Answer

Metformin is an insulin sensitiser that reduces hyperinsulinaemia, lowers androgen levels, and may improve ovulation in PCOS. Its role in fertility treatment is precisely defined by ESHRE 2023 and ASRM 2023.

Indications where metformin is recommended:

1. As adjunct to Letrozole or Clomiphene in overweight/obese women with PCOS (BMI ≥25): ESHRE 2023 recommends adding metformin to oral ovulation induction agents in this group — meta-analyses show improved ovulation rates and lower rates of OHSS compared with oral agent alone.

2. Before and during IVF to reduce OHSS risk: ESHRE 2023 strongly recommends metformin co-administration during ovarian stimulation in PCOS patients undergoing IVF. A 2016 RCT (Kjotrod et al.) and a 2019 Cochrane review (Palomba et al.) both confirm metformin significantly reduces moderate-to-severe OHSS rates without compromising live birth outcomes.

3. Women with PCOS and metabolic comorbidities (impaired glucose tolerance, insulin resistance, metabolic syndrome): Metformin is indicated independently of fertility treatment.

Situations where metformin is NOT the primary treatment:

— Metformin alone is not first-line for ovulation induction: ESHRE 2023 clearly states Letrozole is superior to metformin for live birth rate when the primary goal is ovulation induction. Metformin is an adjunct, not a substitute.
— Normal-weight PCOS with regular cycles: Benefit is less clear; ESHRE 2023 does not recommend routine use in this group.

Standard dosing: 500 mg once daily titrated to 1,500–2,000 mg/day over 4–8 weeks to minimise gastrointestinal side effects. Should be continued through first trimester if pregnancy occurs — ESHRE 2023 notes metformin reduces early pregnancy loss in PCOS.

Question 46

How should obese PCOS patients be managed before IVF?

Dr. Vidhu D · Accepted Answer

Obesity (BMI ≥30 kg/m²) in PCOS significantly impairs IVF outcomes — reducing oocyte quality, endometrial receptivity, implantation rates, and live birth rates while substantially increasing OHSS, miscarriage, and obstetric complication rates.

Pre-IVF management framework (ESHRE 2023, ASRM 2023):

1. Weight loss as the primary intervention: ESHRE 2023 strongly recommends that overweight and obese women with PCOS be offered lifestyle intervention (diet, exercise, behavioural support) before fertility treatment. Even 5–10% weight reduction restores spontaneous ovulation in a significant proportion of anovulatory women and substantially improves IVF outcomes.

2. Multidisciplinary approach: Dietitian, physiotherapist, and psychologist involvement is recommended for structured weight management programmes. A minimum of 3–6 months of lifestyle intervention should be offered before IVF in women with BMI ≥30 — longer programmes produce greater reproductive benefit.

3. Bariatric surgery: ESHRE 2023 notes that bariatric surgery is an option for women with BMI ≥40 (or ≥35 with comorbidities) who fail lifestyle intervention. Fertility treatment should be deferred for at least 12–18 months post-bariatric surgery due to rapid weight loss-related nutritional deficiencies and teratogenic risk. Contraception is essential during this interval.

4. Metformin adjunct: Recommended alongside lifestyle modification for insulin-resistant obese PCOS patients (see Q13).

5. IVF protocol adjustments when proceeding without weight loss:
— AMH-guided low-dose FSH starting dose to reduce OHSS risk
— GnRH antagonist protocol mandatory (enables agonist trigger)
— Freeze-all strategy after agonist trigger
— Anaesthetic and procedural risk assessment for retrieval in high BMI

6. Counsel realistically: ASRM 2023 supports transparent counselling that obesity significantly reduces IVF success rates and increases pregnancy complications — allowing fully informed decision-making.

Question 47

Should all embryos be frozen in PCOS patients at risk of OHSS?

Dr. Sarah H · Accepted Answer

Yes — a freeze-all strategy is strongly recommended for PCOS patients at risk of OHSS, and is now considered standard care in this group when a GnRH agonist trigger is used.

Evidence base:

The Shi et al. NEJM 2018 RCT (n=1,508 anovulatory women, primarily PCOS) directly addressed this question. Freeze-all strategy followed by frozen embryo transfer (FET) showed significantly higher live birth rates compared with fresh embryo transfer (49.3% vs 42.5%, p=0.004), with lower OHSS rates in the freeze-all group.

Why freeze-all is mandated when agonist trigger is used: GnRH agonist trigger — the cornerstone of OHSS prevention — causes premature luteolysis, making the endometrium unreceptive for fresh transfer. Freeze-all and subsequent FET eliminates this problem entirely.

Why freeze-all is beneficial even beyond OHSS prevention in PCOS:
— PCOS is associated with an elevated LH environment during fresh cycles, which may impair endometrial receptivity for fresh transfer
— Elevated progesterone at time of trigger (common in PCOS hyperstimulation) is associated with premature endometrial advancement and reduced implantation
— The Shi trial confirms a clinical pregnancy and live birth advantage for freeze-all in PCOS independent of OHSS

ESHRE 2023 position: Freeze-all is recommended for all PCOS patients undergoing IVF where agonist trigger is used. It should be considered even when hCG trigger is used if progesterone rise is noted or OHSS risk is elevated.

ASRM 2023: Endorses freeze-all as standard of care in high-OHSS-risk patients; notes the PCOS-specific live birth benefit demonstrated by the Shi trial.

Question 48

How should recurrent implantation failure be approached in women with PCOS?

Dr. Sarah H · Accepted Answer

Recurrent implantation failure (RIF) in PCOS has specific aetiological contributors beyond the general RIF workup, related to the unique endocrine and metabolic milieu of the condition.

PCOS-specific contributors to RIF:

1. Endometrial dysfunction: PCOS-associated hyperinsulinaemia and androgen excess impair endometrial HOXA10/HOXA11 expression and integrin αvβ3 — key implantation mediators. Metformin may partially restore endometrial receptivity.

2. Elevated LH during stimulation: In non-antagonist cycles or cycles with premature LH rise, endometrial advancement can desynchronise implantation window from embryo stage.

3. Premature progesterone rise: Common in PCOS hyperstimulation — progesterone >1.5 ng/mL on day of trigger is associated with reduced implantation. Freeze-all eliminates this problem.

4. Suboptimal endometrial preparation in FET cycles: SNC-FET (stimulated natural cycle) is preferred over HRT-FET in anovulatory PCOS — exogenous oestrogen-only preparation may not adequately suppress endogenous hormonal fluctuation.

5. Chronic endometritis: Prevalence in RIF-PCOS may be higher than in general RIF population — CD138 biopsy is indicated.

Management approach (ESHRE 2024 RIF Guideline):
— Freeze-all strategy to eliminate fresh-transfer endometrial issues
— SNC-FET with ultrasound monitoring preferred for PCOS
— Optimise insulin sensitivity (metformin, weight loss) before repeat transfers
— Assess and treat chronic endometritis (CD138 biopsy, antibiotic treatment if positive)
— Consider hysteroscopy to exclude intracavitary pathology
— PGT-A if blastocyst pool permits — aneuploidy remains a significant cause of RIF in all populations

Question 49

How is recurrent implantation failure currently defined?

Dr. Sarah H · Accepted Answer

There is no single universally accepted definition of recurrent implantation failure (RIF), which has historically hampered research and clinical comparison. However, ESHRE published its first dedicated RIF Guideline in 2023 (updated 2024) which provides the most current and clinically applicable definition.

ESHRE 2024 RIF Definition: The failure of at least three embryo transfers of one or more good-quality embryos, or the failure of cumulative transfer of at least four embryos (of any quality) in at least three fresh or frozen cycles in a woman under 40 years of age.

Practical clinical threshold used in most centres: Two or more failed transfers of good-quality blastocysts (morphologically selected, or euploid after PGT-A). This pragmatic threshold is supported by ASRM 2023 as a reasonable starting point for investigation.

Important distinctions in the definition:
— RIF requires implantation failure (no clinical pregnancy), not pregnancy loss — recurrent miscarriage after implantation is classified as recurrent pregnancy loss (RPL)
— "Good-quality embryo" should be defined using Istanbul consensus morphology criteria (≥BB grade blastocyst) or confirmed euploid status after PGT-A
— The definition differs for euploid embryo transfer (RIF-e): two failed euploid FETs is sufficient to trigger investigation per most expert guidelines, given the high expected implantation rate per euploid embryo (50–65%)

Age threshold: The ESHRE 2024 definition applies to women under 40. In women ≥40, reduced implantation rates per transfer are expected even with good-quality embryos — a higher threshold of failures may be required before formal RIF investigation is warranted.

Question 50

What investigations are recommended after three failed embryo transfers?

Dr. Sarah H · Accepted Answer

After three failed embryo transfers, a systematic investigation guided by ESHRE 2024 RIF Guideline is indicated. The workup should be targeted, evidence-based, and avoid tests without established treatment pathways.

Recommended investigations (ESHRE 2024 — strong evidence):

Uterine assessment:
— 3D transvaginal ultrasound (preferred) or saline infusion sonography: to exclude uterine septum, submucosal fibroids, polyps, and intrauterine adhesions
— Hysteroscopy: gold standard for diagnosis and simultaneous treatment of intracavitary pathology

Endometrial assessment:
— Endometrial biopsy for CD138 immunohistochemistry: to diagnose chronic endometritis (CE). Prevalence in RIF is 14–57%; treatment of confirmed CE significantly improves subsequent implantation rates (Cicinelli et al., 2018)

Immunological/thrombotic screening:
— Antiphospholipid antibody syndrome (APS) panel: lupus anticoagulant, anticardiolipin IgG/IgM, anti-β2-GP1, confirmed on two occasions ≥12 weeks apart
— NOT recommended: routine NK cell testing, cytokine panels, HLA typing — insufficient evidence per ESHRE 2024

Sperm assessment:
— Sperm DNA fragmentation (SDF) if not previously performed — SCSA DFI >30% is associated with RIF

Embryological review:
— Laboratory KPI audit: fertilisation rate, blastulation rate, embryo morphology — a sudden decline may indicate a lab quality issue rather than a patient factor
— Consider PGT-A if blastocyst pool is adequate — aneuploidy is the most common cause of failed implantation

ERA (endometrial receptivity analysis): NOT recommended for routine use — both the SIFEM (NEJM 2023) and TIME (Fertil Steril 2022) RCTs showed no live birth benefit in unselected RIF populations.

Question 51

What investigations should be performed in recurrent miscarriage?

Dr. Sarah H · Accepted Answer

A structured, evidence-based workup for recurrent miscarriage (recurrent pregnancy loss — RPL) is recommended after two confirmed losses (ASRM 2023) or three losses (ESHRE 2022), and earlier in women over 35 years.

Investigations with strong evidence (ESHRE 2022, ASRM 2023 — recommended):

1. Antiphospholipid antibody syndrome (APS) panel:
— Lupus anticoagulant
— Anticardiolipin antibodies IgG and IgM
— Anti-β2-glycoprotein-I IgG and IgM
— Must be positive on two occasions ≥12 weeks apart to confirm diagnosis
— APS is the most important treatable cause of RPL; treatment (aspirin + LMWH) significantly reduces further pregnancy loss

2. Uterine anatomy:
— 3D transvaginal ultrasound (preferred — best sensitivity and specificity for uterine septum)
— Hysteroscopy if 3D TVS is inconclusive or surgical correction is planned

3. Parental karyotyping (both partners):
— Detects balanced translocations and other structural chromosomal rearrangements — found in approximately 3–5% of RPL couples
— Results guide genetic counselling and potential use of PGT-SR

4. Thyroid function (TSH):
— Subclinical hypothyroidism (TSH >2.5 mIU/L) is associated with increased RPL; levothyroxine treatment is recommended

5. Product of conception (POC) genetics:
— Chromosomal analysis of pregnancy tissue after each loss — identifies aneuploidy as the cause (present in ~50% of first-trimester losses)
— CGH-microarray preferred over standard karyotype (higher detection rate)

Not recommended by ESHRE 2022 (insufficient evidence):
— Inherited thrombophilia panel (Factor V Leiden, prothrombin G20210A, protein C/S, antithrombin)
— NK cell testing, HLA typing, cytokine profiling
— Antinuclear antibody screening as routine

Question 52

What is the evidence for aspirin and heparin in recurrent pregnancy loss?

Dr. Sarah H · Accepted Answer

The use of aspirin and low molecular weight heparin (LMWH) in RPL is context-specific — the evidence strongly supports their use in confirmed antiphospholipid antibody syndrome (APS) but does not support routine use in unexplained RPL or inherited thrombophilia without APS.

Confirmed APS (most important indication):
The combination of aspirin 75–100 mg/day + LMWH (enoxaparin 40 mg/day or dalteparin 5,000 IU/day) from positive pregnancy test onward is the evidence-based standard of care for obstetric APS. A 2005 Cochrane review (Empson et al.) and subsequent meta-analyses confirm this combination significantly reduces pregnancy loss in APS compared with aspirin alone or no treatment.

ESHRE 2022 and ASRM 2023 both give this a strong recommendation with high evidence quality.

Unexplained RPL (no APS):
The ALIFE trial (de Jong et al., NEJM 2010): n=364 women with unexplained RPL and inherited thrombophilia or idiopathic RPL. LMWH + aspirin showed no benefit over aspirin alone or no treatment for live birth rate. This definitively ended the practice of prescribing anticoagulants for unexplained RPL without APS.

The ALIFE2 trial (Quenby et al., Lancet 2015): n=287 women with inherited thrombophilia and RPL. Nadroparin showed no improvement in live birth rate vs placebo.

ESHRE 2022: Does NOT recommend aspirin or LMWH for unexplained RPL in the absence of APS. This is a strong recommendation against routine use.

Aspirin alone (low-dose):
No robust RCT evidence supports aspirin monotherapy for unexplained RPL. The PROMISE trial (Coomarasamy, NEJM 2015) tested progesterone, not aspirin — these should not be conflated.

Question 53

How should unexplained recurrent pregnancy loss be managed?

Dr. Vidhu D · Accepted Answer

Unexplained RPL — defined as three or more pregnancy losses with no identifiable cause after full workup (ESHRE 2022) — accounts for approximately 50% of all RPL cases. Management is both medical and supportive.

Evidence-based interventions:

1. Vaginal progesterone: The PRISM trial (Coomarasamy et al., NEJM 2019; n=4,153) showed vaginal micronised progesterone 400 mg BD from positive pregnancy test to 12 weeks significantly improved live birth rate in women with prior miscarriage and early pregnancy bleeding (72% vs 67%, p=0.008). Subgroup analysis of women with ≥3 prior losses showed a 15% absolute benefit. ESHRE 2022 recommends vaginal progesterone for unexplained RPL.

2. Supportive care in a dedicated early pregnancy unit: Multiple studies (Brigham et al., Fertil Steril 1999; Liddell et al.) show that intensive supportive surveillance — serial hCG monitoring, early ultrasound, dedicated nursing — reduces anxiety and improves live birth rates in unexplained RPL even without pharmacological intervention. The mechanism is thought to involve reduced stress-related neuroendocrine disruption.

3. Lifestyle optimisation:
— Smoking cessation: associated with significantly increased miscarriage risk
— BMI normalisation (18.5–25): obesity and underweight both increase RPL risk
— Alcohol and caffeine reduction

4. PGT-A (preimplantation genetic testing): For couples with unexplained RPL who proceed to IVF, PGT-A reduces miscarriage rate after transfer (by selecting euploid embryos). ESHRE 2022 notes PGT-A is a reasonable option in this context.

What NOT to use in unexplained RPL (ESHRE 2022):
— LMWH without APS: no evidence (ALIFE, ALIFE2 trials)
— Immunological treatments (intravenous immunoglobulin, TNF-α inhibitors, lymphocyte immunotherapy): insufficient evidence; not recommended outside research

Question 54

When should parental karyotyping be advised?

Dr. Michael C · Accepted Answer

Parental karyotyping identifies chromosomal abnormalities — primarily balanced translocations and inversions — that are carried silently by one or both parents but cause chromosomally unbalanced pregnancies, leading to miscarriage.

Prevalence: Approximately 3–5% of RPL couples carry a balanced chromosomal rearrangement in one or both partners, compared with 0.2% of the general population.

Indications (ESHRE 2022, ASRM 2023):

1. Two or more confirmed pregnancy losses (ASRM 2023 — aligns with updated RPL definition of ≥2 losses)
2. One or more pregnancy affected by a chromosomal abnormality on POC analysis
3. Known family history of chromosomal rearrangement
4. Prior child born with chromosomal abnormality
5. Severe oligospermia or azoospermia in male partner (increased rate of sperm chromosomal abnormalities and paternal balanced translocations)

Clinical implications of a positive result:

— Reciprocal translocations: Approximately 50–75% of conceptions will be chromosomally unbalanced (depending on the specific translocation). PGT-SR (preimplantation genetic testing for structural rearrangements) identifies unbalanced embryos before transfer and is strongly recommended.

— Robertsonian translocations: Risk of unbalanced offspring depends on specific chromosomes involved. Rob(13;14) carriers have a lower risk than Rob(21;21) carriers — the latter cannot have unaffected biological children without donor gametes.

— Inversions: Paracentric inversions carry low recombination risk; pericentric inversions carry higher risk of unbalanced offspring — PGT-SR is indicated.

Genetic counselling is mandatory when a parental chromosomal abnormality is identified.

Question 55

What are the common genetic causes of recurrent miscarriage?

Dr. Michael C · Accepted Answer

Genetic factors are the single most common identifiable cause of individual and recurrent pregnancy loss. The contribution of genetics operates at two levels: embryonic (sporadic aneuploidy) and parental (structural chromosomal rearrangements).

1. Embryonic aneuploidy (most common cause overall):
Chromosomal aneuploidy accounts for approximately 50–60% of all first-trimester losses. Common aneuploidies include: Trisomy 16 (most common; always lethal), Trisomy 21, 18, 13, monosomy X (Turner), and triploidy. The aneuploidy rate increases steeply with maternal age — in women over 40, 70–80% of losses are aneuploid. Product of conception (POC) chromosomal analysis by CGH-microarray confirms aneuploidy as the cause of each specific loss.

2. Parental balanced translocations:
Present in 3–5% of RPL couples (vs 0.2% in general population). Types:
— Reciprocal translocations: segments exchanged between non-homologous chromosomes
— Robertsonian translocations: acrocentric chromosomes (13, 14, 15, 21, 22) fuse at centromere
PGT-SR before IVF can identify embryos with unbalanced karyotypes for exclusion from transfer.

3. Uniparental disomy (UPD) and imprinting errors:
Imprinting disorders (Angelman syndrome, Prader-Willi) arise from UPD in a normally diploid embryo — detectable by methylation analysis on POC.

4. Single gene disorders:
Rare. Factor V Leiden homozygosity (not heterozygosity) carries an elevated thrombotic and possibly RPL risk. MTHFR variants (C677T, A1298C) — previously believed to cause RPL — are NOT now considered causative per ESHRE 2022; routine testing is not recommended.

5. X-linked causes (male partner):
Klinefelter syndrome (47,XXY) is associated with higher rates of aneuploid sperm and recurrent early pregnancy loss. Sperm aneuploidy testing may be warranted in selected cases.

Question 56

How does severe endometriosis affect embryo quality?

Dr. James M · Accepted Answer

Severe endometriosis (Stage III–IV; deep infiltrating endometriosis or large endometriomas) has been shown to adversely affect multiple aspects of reproductive function, including oocyte and embryo quality, though the mechanisms remain incompletely understood.

Evidence on oocyte and embryo quality:

Follicular environment: Endometrioma-associated oxidative stress (reactive oxygen species from haem degradation products) damages granulosa cells and cumulus cells adjacent to the cyst. Elevated iron, reactive oxygen species, and inflammatory cytokines in the follicular fluid of endometrioma-bearing ovaries impair oocyte nuclear and cytoplasmic maturation.

Oocyte competence: A 2014 meta-analysis (Hamdan et al., Hum Reprod) found that women with endometriomas produced fewer mature oocytes per cycle compared to controls (weighted mean difference: −0.5 MII oocytes). Fertilisation rate per MII oocyte was not significantly different, suggesting the impact is primarily on oocyte yield rather than inherent fertilising capacity.

Embryo quality: Studies comparing blastocyst formation and morphology grades in endometriosis vs non-endometriosis IVF cycles are conflicting. A 2016 systematic review (Barbosa et al.) found no statistically significant difference in embryo quality when oocyte numbers were matched. However, a 2022 cohort study (Sanchez AM et al.) reported lower mitochondrial content in oocytes from endometrioma-affected ovaries, suggesting sub-clinical cytoplasmic competence impairment.

Impact on euploidy rate: ESHRE 2022 Endometriosis Guideline notes that PGT-A data do not conclusively demonstrate a higher aneuploidy rate per blastocyst in endometriosis compared with age-matched controls without endometriosis.

Practical implications: Reduced oocyte yield is the primary IVF concern in severe endometriosis. Embryo quality per retrieved oocyte is not substantially different in most studies, provided optimal laboratory conditions are maintained.

Question 57

What are the latest ESHRE recommendations on endometriosis-associated infertility?

Dr. James M · Accepted Answer

The ESHRE Endometriosis Guideline (2022) provides the most comprehensive current evidence-based recommendations for managing endometriosis in the context of infertility.

Key recommendations:

1. Surgical treatment of minimal/mild endometriosis (Stage I/II) before IVF:
ESHRE 2022 recommends laparoscopic treatment of Stage I/II endometriosis when incidentally found at the time of diagnostic laparoscopy, as it improves spontaneous pregnancy rates (Marcoux et al., NEJM 1997; Parazzini et al.). Benefit specifically for IVF outcomes is less clear — a 2010 Cochrane review found insufficient evidence that surgery improves IVF outcomes in Stage I/II.

2. Endometriomas before IVF: Surgery should NOT be performed routinely before IVF (see Q23 detail). Ovarian reserve reduction outweighs any potential benefit.

3. Stage III–IV endometriosis before IVF:
— Prolonged GnRH agonist suppression (3–6 months) before IVF significantly improves clinical pregnancy rates in Stage III–IV endometriosis (Sallam et al., Cochrane 2006; Guo et al., Fertil Steril 2019)
— ESHRE 2022 recommends offering this to women with moderate-severe endometriosis before IVF

4. Medical suppression does not restore fertility:
— Hormonal treatments (combined pill, progestogens, GnRH agonists) used to suppress endometriosis do not improve natural fertility — they prevent conception during treatment. They should not be prescribed as a fertility strategy.

5. Assisted reproduction for endometriosis:
— IVF is indicated when tubes are blocked, male factor coexists, or other treatments have failed
— IUI may be appropriate for Stage I/II endometriosis with patent tubes and normal sperm
— IVF outcomes in endometriosis are generally comparable to other diagnoses when oocyte yield is adequate

6. Pain management alongside fertility treatment:
— Endometriosis-associated pain should be managed alongside fertility planning — not sacrificed for it

Question 58

What is the optimal interval between surgery and IVF in endometriosis?

Dr. James M · Accepted Answer

The timing of IVF after endometriosis surgery must balance two competing concerns: allowing adequate tissue healing and AMH recovery, while not losing additional ovarian reserve or reproductive time — particularly critical in older women.

Evidence on AMH recovery after endometriomectomy:
AMH declines immediately after ovarian cystectomy (stripping technique) and may fall by 30–50% per operated ovary. Multiple longitudinal studies (Raffi et al., Fertil Steril 2012; Somigliana et al., 2015) show that AMH partially recovers over 3–6 months post-surgery but rarely returns to pre-operative levels, and the degree of recovery is unpredictable.

ESHRE 2022 recommendation:
There is no high-quality RCT defining the optimal interval between endometriosis surgery and IVF. ESHRE 2022 does not specify a mandatory waiting period but makes several practical recommendations:
— Allow minimum 6–8 weeks for tissue healing after laparoscopic cystectomy before stimulation
— Repeat AMH and AFC at 3 months post-surgery before committing to IVF — allows assessment of actual post-operative reserve
— For women with significant pre-operative DOR or advanced age (≥38), minimise delay: consider stimulating at 6–8 weeks post-op or deferring surgery altogether
— Prolonged GnRH agonist suppression (3–6 months) before IVF in Stage III–IV: this suppression period itself serves as the pre-IVF interval and may improve outcomes (Guo et al., 2019)

Practical guidance: Women under 35 with good pre-operative AMH can afford a 3–6 month post-surgical interval. Women ≥38 or with pre-operative AMH <1.5 ng/mL should minimise delay — the cost of waiting exceeds the benefit of further healing.

Question 59

How should deep infiltrating endometriosis be managed in infertile patients?

Dr. James M · Accepted Answer

Deep infiltrating endometriosis (DIE) — defined as endometriosis penetrating ≥5 mm beneath the peritoneal surface — affects the rectovaginal septum, uterosacral ligaments, bladder, ureter, and bowel. Its management in infertile patients requires careful individualisation.

Key management principles (ESHRE 2022):

1. Surgical vs expectant approach — evidence is limited:
— No RCT specifically addresses whether DIE excision improves IVF outcomes in infertile patients
— Retrospective evidence (Ballester et al., Hum Reprod 2012) suggests DIE resection before IVF may improve oocyte yield and clinical pregnancy rates in severe cases
— ESHRE 2022 states: surgical treatment of DIE for fertility should not be performed solely to improve IVF outcomes — the potential benefit must be weighed against substantial surgical risk

2. Surgical risk is significant:
— DIE surgery carries risks of bowel injury, ureteric injury, bladder damage, nerve damage, and de novo pelvic adhesions
— Requires a highly specialised endometriosis surgical centre
— Complication rates are 2–10% depending on lesion location and complexity

3. Prolonged GnRH agonist before IVF:
— For women with DIE declining surgery or not yet surgical candidates, 3–6 months of GnRH agonist pre-treatment before IVF is recommended by ESHRE 2022 — reduces inflammatory cytokine burden and improves implantation environment

4. Pain-fertility balance:
— If DIE is causing severe pain (bowel obstruction risk, ureteric obstruction, severe dyspareunia), surgery is indicated on its own clinical merits — fertility benefit is a secondary consideration
— Where pain is managed medically, direct IVF without surgery is appropriate

5. IVF outcomes in DIE:
— Studies show IVF outcomes in DIE patients are comparable to age-matched controls when adequate oocytes are obtained (Garcia-Velasco, 2015)
— Cumulative live birth rates are primarily limited by reduced oocyte yield, not implantation failure

Question 60

What are the latest guidelines for evaluating severe oligozoospermia?

Dr. James M · Accepted Answer

Severe oligozoospermia is defined as a sperm concentration <5 million/mL (WHO 2021 fifth edition reference values). It is clinically distinct from moderate oligozoospermia and from azoospermia, and warrants a structured evaluation to identify a treatable underlying cause.

Evaluation framework (EAU 2024, ASRM 2023):

1. Semen analysis confirmation:
— A minimum of two semen analyses (ideally three), at least 4 weeks apart, are required before diagnosis is confirmed (WHO 2021; ASRM 2023)
— Both WHO 2010 (5th edition) and WHO 2021 thresholds apply: concentration <16 million/mL = oligozoospermia; <5 million/mL = severe; <1 million/mL = cryptozoospermia (near-azoospermia)

2. Hormonal profile:
— FSH, LH, total testosterone, prolactin, SHBG
— Elevated FSH with low testosterone = primary testicular failure (Sertoli cell/germinal epithelium dysfunction)
— Low FSH + low testosterone = hypogonadotrophic hypogonadism (treatable with gonadotrophins)
— Normal FSH with severe oligozoospermia = possible obstruction or genetic cause

3. Genetic testing (mandatory in severe oligozoospermia):
— Karyotype: detects Klinefelter syndrome (47,XXY) and other sex chromosome abnormalities
— Y chromosome microdeletion panel (AZFa, AZFb, AZFc): AZFc deletions are found in approximately 6–13% of severe oligozoospermia cases and are compatible with sperm retrieval
— CFTR mutation testing: if congenital absence of the vas deferens suspected

4. Scrotal ultrasound: Detects varicocele (most common correctable cause), testicular atrophy, epididymal abnormalities, or testicular tumour

5. Testicular biopsy: Only indicated if clinical picture suggests obstruction despite absent vas or normal FSH, to confirm spermatogenesis before surgical correction

Question 61

How should elevated sperm DNA fragmentation be treated?

Dr. James M · Accepted Answer

Elevated sperm DNA fragmentation (SDF) — defined as SCSA DFI ≥25–30% or TUNEL >15% — reduces IVF/ICSI success and increases miscarriage rate. Treatment targets modifiable causes and optimises sperm source for ART.

Evidence-based treatment strategies (EAU 2024, ASRM 2023):

1. Varicocele repair (highest evidence):
— Varicocele is associated with elevated SDF through oxidative stress and hyperthermia
— A 2016 meta-analysis (Kirby et al., Fertil Steril) and subsequent RCTs confirm varicocelectomy significantly reduces SDF (mean DFI reduction of approximately 10 percentage points)
— EAU 2024: Varicocele repair is recommended for clinical varicocele with elevated SDF, regardless of standard semen parameters

2. TESE-ICSI (testicular sperm extraction + ICSI):
— Testicular sperm consistently shows significantly lower SDF than ejaculated sperm from the same man (mean DFI 10–15% vs 25–35%)
— A 2022 meta-analysis (Esteves et al., Andrology; 15 studies) confirmed significantly higher live birth rates with TESE-ICSI vs ejaculate-ICSI when ejaculatory DFI >30%
— EAU 2024 and ASRM 2023 both endorse testicular sperm as the preferred source when ejaculatory SDF is markedly elevated

3. Antioxidant supplementation:
— Vitamin C, E, CoQ10, lycopene, selenium — proposed to reduce oxidative damage to sperm DNA
— Evidence from individual RCTs is positive for semen parameter improvement, but a 2019 Cochrane review (Smits et al.) found insufficient evidence that antioxidants improve live birth rates
— Pragmatic use (3–6 months before IVF) is reasonable given low cost and safety; not a substitute for TESE or varicocele repair

4. Genital tract infection treatment:
— Undiagnosed or subclinical genital tract infections (chlamydia, mycoplasma, E. coli) are associated with elevated SDF — seminal culture and targeted antibiotic treatment may reduce SDF

5. Lifestyle modification:
— Smoking cessation, heat avoidance, reducing alcohol

Question 62

What are the indications for Y chromosome microdeletion testing?

Dr. James M · Accepted Answer

Y chromosome microdeletions occur in the AZF (azoospermia factor) region on the long arm of the Y chromosome (Yq11) and are the most common known genetic cause of non-obstructive azoospermia (NOA) and severe oligozoospermia, found in approximately 15% of NOA and 5–10% of severe oligozoospermia cases.

Indications for Y chromosome microdeletion testing (EAU 2024, ASRM 2023):

Primary indications:
— Non-obstructive azoospermia (mandatory before micro-TESE)
— Severe oligozoospermia (<5 million/mL)
— Cryptozoospermia (<1 million/mL)

Three AZF regions and clinical significance:

AZFa deletion (complete): Sertoli-cell-only syndrome — no sperm retrieval is possible on micro-TESE. Testing before TESE prevents futile surgery. EAU 2024: micro-TESE should NOT be offered.

AZFb deletion (complete): Maturation arrest at spermatocyte stage — sperm retrieval is highly unlikely (<1–2%). TESE is generally not recommended.

AZFc deletion (most common — approximately 70% of all Y deletions): Spermatogenesis is present but severely impaired. Sperm retrieval with micro-TESE is successful in approximately 50–70%. Y microdeletion is transmitted to all male offspring — genetic counselling is essential before ICSI.

Why the result changes management:

— AZFa or AZFb: Avoid surgical sperm retrieval; counsel donor sperm as the primary path
— AZFc: Proceed to micro-TESE; counsel about vertical transmission to sons
— gr/gr deletion (partial AZFc): Associated with increased risk of oligozoospermia in offspring — counselling required

EAU 2024: Y microdeletion testing is mandatory before IVF/ICSI with testicular sperm in NOA patients, and is recommended in severe oligozoospermia.

Question 63

How should non-obstructive azoospermia be managed?

Dr. James M · Accepted Answer

Non-obstructive azoospermia (NOA) — where no sperm are present in the ejaculate due to primary testicular failure rather than obstruction — requires a systematic approach to establish aetiology, counsel realistically, and pursue sperm retrieval if indicated.

Management pathway (EAU 2024, ASRM 2023):

1. Confirm NOA diagnosis:
— Two centrifuged semen analyses showing azoospermia
— Elevated FSH, reduced testicular volume, normal ductal anatomy (palpable vas, no epididymal dilation)

2. Mandatory genetic evaluation before any procedure:
— Karyotype: Detects Klinefelter syndrome (47,XXY) — the most common cause of NOA, found in ~14%
— Y chromosome microdeletion: AZFa or AZFb complete deletion = micro-TESE not indicated; AZFc = proceed with counselling

3. Hormonal optimisation before micro-TESE (selected cases):
— Hypogonadotrophic hypogonadism (low FSH, low testosterone): gonadotrophin stimulation can restore spermatogenesis — this is the only NOA subtype that responds to medical treatment
— For primary NOA with low testosterone + high FSH: a 3–6 month trial of clomiphene citrate or tamoxifen may improve testosterone and potentially retrieval rates (Reifsnyder et al., Fertil Steril 2012)

4. Surgical sperm retrieval — micro-TESE:
— Microscopic testicular sperm extraction (micro-TESE) is the gold standard for NOA — overall success rate approximately 50–60%
— Should be performed by an experienced uroandrologist at a high-volume centre
— Simultaneous ICSI with retrieved sperm is preferred; cryopreservation of retrieved sperm is the alternative

5. If micro-TESE fails:
— Repeat micro-TESE after 6–12 months (some evidence of success on second attempt)
— Donor sperm insemination or IVF should be discussed before the first micro-TESE — so patients are not left without a plan

Question 64

What causes sudden deterioration in fertilisation rates?

Dr. James M · Accepted Answer

A sudden unexplained drop in fertilisation rate — defined as falling below 70% of MII oocytes in ICSI cycles (ESHRE Alpha KPI threshold) — requires systematic root cause analysis across equipment, consumables, personnel, and patient factors.

Common causes by category:

Equipment and incubator issues (highest priority):
— CO₂ incubator failure: CO₂ drift (even 0.5% change) alters media pH and disrupts embryo development within hours. Check CO₂ readout, calibrate with a CO₂ meter, and inspect CO₂ cylinder connection
— Temperature instability: Thermostat malfunction can cause embryo arrest. Verify all incubator thermometers; check heated stage temperatures during ICSI
— ICSI micromanipulator: Needle bevel wear, clogged injection pipette, or heating stage malfunction can damage oocytes during injection

Culture media and consumables (second priority):
— Media lot change: A new lot of fertilisation or culture medium may contain cytotoxic contaminants. Always quality test new lots before clinical use. Revert to previous lot if suspicion is high
— Oil quality: Mineral oil covering droplets can become toxic if contaminated or old — replace immediately
— Dish or plasticware: Rare manufacturing defects or incorrect plasticware type (polystyrene vs tissue-culture-treated) can be embryotoxic
— Water quality: The water system supplying the IVF lab must maintain <0.5 EU/mL endotoxin; a spike in endotoxin can devastate fertilisation rates

Personnel and technique:
— New embryologist or technique change: ICSI degeneration rate should be tracked by operator. A rate >10% warrants review of technique
— Denudation timing or enzyme concentration

Patient-related (last to exclude):
— Poor oocyte quality (patient batch effect): Can occur with a specific stimulation protocol change or patient cohort

REI Specialist Q&A — Evidence-Based Clinical Answers on IVF, PGT-A & Fertility

IVF Stimulation & Poor Responders

PCOS & Ovulation Induction

Recurrent Implantation Failure

Recurrent Pregnancy Loss

Endometriosis & Fertility

Male Infertility

Embryology & Lab Optimisation

PGT & Reproductive Genetics

Fertility Preservation

IVF Outcomes & Counselling

India-Specific IVF Practice

Browse by Clinical Topic